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ABSTRACT 
 In the fight against disease and illness, nature has provided mankind some of our 
best therapeutics in the form of secondary metabolites. The plant, fungi and animal 
phyla inhabiting the Earth produce diverse and unique chemistry that can be used in our 
fight against disease. In the growing threat of drug resistance and pathogen evolution, 
the field of natural products chemistry strives to explore new biological and chemical 
diversity sources, and develop innovative methodology to identify and isolate new 
chemistry faster than ever.  
 The dissertation herein presented is one such effort to find new, bioactive 
chemistry from the marine environments. New biodiversity sources, from the tropical 
Floridian mangrove forests to the cold waters of the Antarctic oceans, were evaluated 
for the new, unique chemistry they produce. A large-scale screening of epigenetically 
modulated mangrove fungi was undertaken, producing a large, biologically and 
chemically diverse extract library. New methodology was developed in order to evaluate 
these extracts, leading to rapid identification and isolation of known and new bioactive 
metabolites. From the Southern Oceans, a collection of sponges was studied, and a 
new, highly unique peptide was isolated and characterized. These efforts were 
undertaken in the continued effort to isolate new, unique lead compounds. 
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CHAPTER ONE: 
NATURAL PRODUCTS AND DRUG DISCOVERY 
 
1.1. History of Natural Products 
1.1.1. Natural Products in Antiquity 
Before the dawn of modern anatomy, medicine, and chemistry, mankind’s grasp 
of health and illness was ruled by the doctrine of humorism. Posited first by 
Hippocrates, humorism viewed all humans as possessing temperaments linked to four 
internal humors: the sanguine blood, aggressive yellow bile, melancholic black bile, and 
peaceful phlegm. The rules of humorism were simple: when all four humors were in 
balance, one was well and healthy; when they were corrupted, one became ill.1 
Unfortunately for mankind, but fortunately for legions of natural product chemists, the 
interaction between humans and their illnesses is far more complex and enduring.  
While early civilizations’ understanding of diseases may have been flawed, 
treatment of illness using plants and herbs was consistent and widespread. Some of the 
earliest documentation of plant-based medicine is from Ancient Mesopotamia, where 
oils from Cedarus sp. (cedar) and Cupressus sempevirens (cypress) trees were used to 
treat coughs and infections; extract from Papaver somniferum (poppy juice) (Figure 
1.1.) is now famous for its use as an anti-infective and powerful painkiller.2 In ancient 
Egypt, pomegranates and date palms were used as antiseptic agents, and to relieve 
2 
 
constipation. Honey was a staple in medicinal practices, used for its anti-infective 
properties, and for preparation and delivery of oral and superficial medicines.3 The 
Chinese Materia Medica, the most extensive and enduring ancient medicinal 
encyclopedia, records hundreds of herbal and plant remedies, the most well-known of 
which is the use of ginseng (Panax sp.) by the wealthy classes for increased 
intelligence and mental capability.2,4 In the Americas, Californian Indian tribes used 
steeped bark and leaves of Artemisia californica (American Sagebrush) in alcohol to 
create a powerful painkiller often used during labor and for serious wounds.5 
 
Figure 1.1. Seed capsule of Papavar somniferum, from which opium is derived.6 
While these ancient cultures certainly understood the usefulness of these natural 
remedies, the mechanisms by which they worked was elusive to them. Magic and 
religious rituals were frequently incorporated in tandem with these medicines, and this 
interaction was often credited for convalescence.2–5 But it wasn’t the ritual factors that 
gave these extracts their medicinal properties; the properties of these plants and herbs 
are a result of the metabolites that they produce, and that are extracted to make 
medicine. It is not the poppy seed itself that acted as a painkiller and antibiotic. It is 
3 
 
morphine and codeine, the most prevalent alkaloids present in crude poppy extracts,2 
that are responsible, by binding to selective receptors throughout the central nervous 
system and suppressing their behavior.7–10 The chemical nature of these medicines is 
true of all ancient remedies. Cedar oil is a powerful antibiotic and antifungal agent due 
to the synergistic role of anethole and taxifolin found in plant resin.11–13 Ginseng 
contains high concentrations of ginsenosides like Rb14 which can help increase the 
uptake and release of choline and acetylcholine in the brain, which boosts brain 
development and nerve growth.14–16 The American Sagebrush is useful as a painkiller 
because of the high content of camphor and eucalyptol present in the alcoholic extracts 
of the plants (Figure 1.2.).5,17 
1.1.2. The Nature of Secondary Metabolites 
The chemical constituents of plants and microorganisms maintain important roles 
in society and medicine, and are among the earliest examples of natural products being 
utilized to treat diseases and ailments. Their metabolic origins are critical in 
understanding their role and adapting similar compounds to fight disease. Within all 
living organisms, vast numbers of chemical compounds are taken in and interconverted 
to allow an organism to grow and survive. The metabolic pathways responsible for this 
produce primary metabolites, such as fats, sugars, proteins, and nucleic acids, which 
are ubiquitous and essential for all life. However, there exists secondary metabolic 
pathways, producing compounds with a much more limited distribution in nature. These 
secondary metabolites, coined “natural products”, are often unessential to the growth 
and survival of an organism, but they can play instrumental roles in its productivity and 
fitness.18   
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Morphine   Codeine         Taxifol 
 
 
            Anethole         Ginsenoside Rb                                    Eucalyptol 
 
Figure 1.2. Chemical structures of early, plant-derived natural products used therapeutically. 
 Secondary metabolites can perform a variety of functions in nature, ranging from 
defensive functions to cell signaling and nutrient uptake. Defense of the organism is an 
easily appreciated role of secondary metabolism. Many organisms, particularly sessile 
plants and microorganisms, employ chemical defense to deter predators and to combat 
competition. One of the most clinically relevant examples is the aflatoxin class of 
mycotoxins produced by various species of fungi, including Aspergillus sp. Aflatoxins 
are highly carcinogenic in mammals, and the metabolic derivatives can accumulate in 
tissues, eggs, and milk. Production of such a toxic chemical can deter animal predators 
from consuming the fungi in nature.19,20 Similarly, microorganisms employ chemical 
defenses against other microorganisms. Penicillium spp. are famous for the production 
of antibiotic penicillin-like compounds, providing a key defense for the fungi against 
bacterial competitors (Figure 1.3.).  
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Figure 1.3. Secondary metabolites can play vital biological roles. (A) Fungi can produce 
secondary metabolites with antibiotic properties. Photo by Janice Haney Carr, CDC Public Health 
Image Library. (B) Bacteria can use secondary metabolites to signal the formation of biofilms. 
Copyright © George Barron, University of Guelph, https://atrium.lib.uoguelph.ca , 2013 
 
Secondary metabolites can also play vital roles in the uptake of scare nutrients required 
for growth. Many fungi and bacteria produce siderophores, a class of small, iron-
chelating ligands that can be used to scavenge iron from an otherwise nutrient-poor 
environment. The production of siderophores can greatly increase the absorption and 
utilization of iron within microorganisms.21,22 Secondary metabolites can also serve to 
signal between different organisms of the same species (pheromones) or to signal 
directly or indirectly to organisms of different species (simiochemicals).23 Pheromones 
are chemically and functionally diverse: many insects and mammals use volatile 
chemicals to attract mates,23,24 while plants utilize biologically inactive compounds that, 
in the presence of predator metabolites, react to form volatile pheromones to warn 
neighboring organisms of predation,23 and bacteria utilize polypetide pheromones to 
initiate community-wide activity, including biofilm formation and sporulation. 25 These 
are just a few examples of the many functionally diverse, and often species-specific, 
metabolites that, though unessential for survival, serve vital roles in the success of the 
producing organism.  
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1.1.3. The Origin of Secondary Metabolism 
There have been a number of historical theories to explain the origin of 
secondary metabolism. Some theories viewed secondary metabolism as simply 
“evolution in progress”,26 and that genes encoding for these metabolic pathways are 
persistent, random mutations, or that the secondary metabolism functions as a chemical 
source for potential future use by the organism, much like the mammalian immune 
system.27 These models hold some merit, as most secondary metabolites have no 
discernable purpose or function in the organism unless there is a specific external 
stimulus. Other theories posit that secondary metabolism is only important in how it 
supports primary metabolism, and specifically that secondary metabolites are 
degradation products of primary metabolism, or that they were primary metabolites at 
some point during the compounds existence in the cell.28 Some secondary metabolites 
are derived from primary metabolites or primary metabolic pathways: some 
siderophores like rhodotorluic acid, are derivatives of primary metabolites like citric 
acid,21 and many insect pheromones are degradation productions of plant alkaloids 
(Figure 1.4.).23 However, despite the examples supporting many of these theories, most 
oversimplify the presence and genetic origin of secondary metabolism. The genes that 
encode many secondary metabolites are now known to be consistent throughout many 
generations of a species, and the genes are far too complex to be considered normal 
mutations. The biosynthetic machinery utilized to create secondary metabolites are also 
complex, and in many cases are energetically expensive. Considering the efficiency 
with which primary metabolism occurs, and how its waste and detoxification products 
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are eliminated, it seems unlikely that the advanced secondary metabolic processes 
exist to assist primary metabolism or utilize excess primary metabolites.28 
 
 Monocrotalin        (R)-hydroxydanaidal 
 (Crotalaria spectabilis)       (Male pheromone of 
          Utetheisa ornatrix) 
 
Figure 1.4. Outline of biosynthesis of Utetheisa ornatrix pheromone (R)-hydroxydanaidal from 
plant-host obtained alkaloid monocrotaline.23 
The most widely accepted, unifying model explains secondary metabolism as a 
measure of fitness.28 When resources are plentiful enough to allow primary metabolism 
to be maintained, secondary metabolism allows the organism to thrive, by aiding in 
resource uptake, communication, and to attract or repel other organisms. This model 
unifies the myriad forms and functions of secondary metabolites: siderophores are 
derived from primary metabolites to aid in uptake of scarce nutrients,21,22 pheromones 
are used to attract mates,23,24 and toxins and defensive chemicals aid the organism in 
competing for space and resources11,13,20,25. This model supports the complex genes 
and biosynthetic pathways of secondary metabolism, as well as their persistence 
through generations of a species. It has therefore been largely accepted that secondary 
metabolites serve a role in the fitness of organisms, and that their necessity depends on 
the environmental conditions of the organism, with resource abundance and fierce 
competition inciting the production of unique, bioactive secondary metabolites.  
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1.2. Natural Products as Therapeutics  
1.2.1. Ancient Plant Remedies in the Modern World 
 The development of the modern pharmaceutical industry owes much to the 
herbal remedies that were so invaluable to ancient cultures. Catalogs of these 
medicines, like the “Ebers Papyrus” from Egypt3 and the Chinese Materia Medica,4 
dating to 1500 and 100 BCE respectively, are some of the oldest records of remedies 
and prescriptions known to man. The ancient Greek and Roman empires also 
extensively documented remedies, including formulae and drug interactions, from 
various natural sources. Much of these remedies were best documented by the Arabs, 
who combined much of the Greek, Roman, Chinese, and Indian traditional remedies 
with their own.29 These ancient remedies survived into the modern age, and as the 
pharmaceutical industry evolved, it is no surprise that the plant-derived remedies were 
among the first modern pharmaceuticals. In fact, the first large-scale, commercially 
available drug was morphine, a secondary metabolite used in ancient remedies. While 
the latex of Papaver somniferum seedpods has been collected since antiquity, 
advancements in the extraction and identification allowed the active component to be 
identified and produced commercially.30   
 Perhaps the most clinically relevant of therapeutics from traditional plant 
remedies are plant-derived anti-malarial compounds. Malaria has long been one of 
mankind’s most challenging health issues, heavily impacting the economic and social 
growth of developing nations.31 The first major breakthrough in treatment was the 
discovery of quinine from the bark of Chinchona officinalis, a plant used amongst 
indigenous Amazonian peoples to treat fevers.29,32 Quinine became the first largely 
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distributed drug treatment for malaria, and served as the basis for synthetic analogues, 
chloroquinine and mefloquine, which replaced quinine as malaria treatments in the 20th 
century.29 Following the emergence of resistance to quinine and its derivatives, ancient 
medicines once again served as the scaffold for the next generation of effective anti-
malarial drugs, artemisinin. The Chinese Materia Medica contains descriptions of plant-
based remedies used to treat severe fevers. Subsequently, artemisinin was isolated 
from Artemisia annua,33 and its clinical importance as an effective treatment for malaria 
quickly became apparent,34 and semi-synthetic artemisinin analogues remain as the 
primary treatment for malaria today.35 
 Ancient plant-derived remedies have continued to produce many significant 
commercial drugs. The secondary metabolite paclitaxel, most commonly known by its 
brand name Paclitaxel, is one of the most important anti-cancer drugs in recent years. 
Taxol, along with its precursors, was isolated from the leaves of various Taxus 
species,36 and has been approved for use as a chemotherapy drug against multiple 
types of cancer. Since its approval as a clinical drug, Paclitaxel has generated billions of 
dollars, as well as a suite of semi-synthetically derived and generic chemotherapy  
options.29 Ephedrine, first isolated from Ephedra sinica and described in Traditional 
Chinese Medicine, is a potent anti-asthma medication (Figure 1.5.).29,37 
1.2.2. Microbial Natural Product Pharmaceuticals  
Just as plant remedies have led to important innovations in the therapeutic 
industry, so too have microbial natural products produced some of the milestones drugs 
in the modern age. Historically, microbial sources are underrepresented compared to 
their plant counterparts in their use as therapeutics. 
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Figure 1.5. Examples of landmark natural product drugs. Paciltaxel, isolated from the leaves of 
Taxus brevifolia, photo by Jason Hollinger; artemisinin, isolated from Artemisia annua, photo by 
Kristian Peters; (+)-ephedrine and (-)-ephedrine, isolated from Ephedra sinica, photo by Alex 
Lomas.  
 
As interest in secondary metabolite drugs increased, the breadth of research expanded 
as well. In particular, the last century has shown a large boom in the number of 
microbial-derived therapeutics, beginning with the landmark discovery of 
penicillin.2,29,38,39 The penicillins, first isolated serendipitously by Alexander Fleming from 
the filamentous fungus Penicillium notatum, became the first commercially available, 
broad-spectrum antibiotic, first to aid in the war front of World War II, and later as the 
most commonly used antibiotic.40  
The wild success of the penicillin compounds as antibacterial agents ushered in 
“The Golden Age of Antibiotics”, revolutionizing the search and production of antibiotics, 
many of which were isolated from microorganisms. In addition to the penicillins and their 
synthetic derivatives, cephalosporins, aminoglycosides, and tetracyclines are among 
some of the most important microbial antibiotics. Like plant-derived drugs, microbes 
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have been found to produce chemistry with a broad range of disease targets. Anti-tumor 
compounds like anthracycline, antiparasitics like ivermectin, and immunosuppressive 
agents like cyclosporins and rapamycin demonstrate the broad range of biological 
targets of microbial natural product therapeutics. Like plant-derived remedies, the world 
of microbial natural products has resulted in some of the most important and significant 
drugs of the last century, and continue to be a great source of new therapeutic agents.29 
1.2.3. Rise and Fall of Natural Product Pharmaceuticals 
The field of new chemical entities (NCEs) introduced by the pharmaceutical and 
research fields continues to be dominated by the influence of natural products. Of the 
1,562 NCEs introduced over the last three decades, over 70% are related to natural 
products, being natural products or their derivatives, containing a natural product 
pharmacophore, or mimicking the behavior of natural products.41 Furthermore, most 
NCEs are small molecule drugs, with only ~10% being designated as large biologic 
proteins and macromolecules (B), with 6% being vaccines (Figure 1.6.).41 Natural 
products influences also constitute large portions of NCEs in the most clinically 
prevalent disease areas.  Anti-infective drugs, including antibiotics and antifungals, 
represent almost a quarter of NCEs introduced over the last three decades. Of over 300 
anti-infective NCEs, under 20% are purely synthetic, with natural product derivatives 
and natural product derivatives making up the largest number of compounds.41 
Similarly, anti-cancer NCEs are dominated by natural product derivatives. Fewer than 
20% of anti-cancer NCEs introduced in the last thirty years have been solely synthetic, 
a trend also seen in all anti-cancer drugs since the 1940’s.41 
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Figure 1.6. All new chemical entities (NCEs) from 1981-2014, by type (above), all small molecule 
NCEs by type (below), and description of NCE categories. 41 
 
The impact of natural products, and specifically small molecule natural product drugs, 
on new, active compounds is seen in many other disease areas, those effective against 
diabetes, pain and central nervous system disorders, and parasites. Anti-viral NCEs 
alone are not predominantly natural products and small molecules, with vaccines and 
synthetic molecules making up most of the NCEs introduced in the last thirty years. 
Despite this, many anti-viral NCEs introduced in the last five years include a natural 
product pharmacophore, or are natural product mimics.2,41  
 Despite the dominating influence of natural products on the pharmaceutical 
industry in the last several decades, there has been an undeniable decline in the 
amount of natural product research, and natural product NCEs introduced in the most 
recent 10-15 years. In the early to mid-1980’s, NCEs introduced reached some of its 
highest numbers, with total new drugs introduced routinely surpassing 50 per year. In 
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each subsequent decade, the number of NCEs introduced dropped, from under 40 per 
year in the 1990’s to under 30 per year in the 2000’s, with few outliers (Figure 1.7.).38 
Despite decades of natural product therapeutic developments, the last several decades 
have shown a decreased interest in natural products within pharmaceutical research.  
The decline of research investment into natural products was brought about by a 
shift in techniques for searching for new therapeutics. The standard screening and 
development process of natural product research has many drawbacks: the expenses, 
time, and effort invested into developing new, active compounds can be significant. 
 
Figure 1.7. Total number of small molecule natural products introduced per year over the last 30 
years (1981-2014).41 
 
Meanwhile, obtaining biodiversity to study can be rigorous, novel compounds become 
more difficult to find, and scaling up production of new compounds is a critical hurdle of 
drug development.42 Biological assay technology, however, has grown more efficient, 
and there have been huge advancements in research of the genomic and molecular 
targets of many disease organisms. The pace of high-throughput screening (HTS) 
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against phenotypic and molecular target assays quickly outstripped the supply of single 
natural products introduced for the first time, and the traditional natural product research 
paradigm seemed incompatible with new screening technologies. In order to address 
this issue, the pharmaceutical industry turned to large combinatorial libraries, consisting 
of tens of thousands of synthetic compounds and derivatives, which could be 
developed, maintained, and screened at a much faster rate than competing natural 
product libraries.43 The shift to combinatorial chemistry greatly diminished the amount of 
natural products research seen in recent decades.   
1.2.4. The “New Golden Age” of Natural Products 
While large, combinatorial libraries dominated much of the pharmaceutical 
industry for the past twenty years, the return of new, clinically useful drugs has been 
almost non-existent. Specifically, only two examples of de novo compounds approved 
as drugs have been generated by the vast amount of combinatorial chemistry that 
dominated the pharmaceutical industry (Figure 1.8.). The first, sorafenib, was 
developed by Bayer and was first approved in 2005 as an anti-cancer drug, with activity 
against various forms of cancer and carcinomas.41 Additionally, ataluren was reported 
and approved in 2014 to treat rare genetic disorders.44 Despite the clinical relevance of 
these two compounds, the success rate of combinatorial libraries pales in comparison to 
the natural product NCEs introduced and approved over the same time period. From 
2005-2014, the time frame during which both sorafenib and ataluren were approved, 
~200 new drugs have been approved that would be classified as a natural product or 
natural product derivative, or a synthetic drug containing or mimicking natural product 
chemistry.41 With the underwhelming success of combinatorial libraries, a renewed 
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investment in natural product chemistry has seen an increase in natural product NCEs 
in the last few years, leading to a “New Golden Age of Natural Products” chemistry.45 
 
 Figure 1.8. Chemical structures of ataluren (left) and sorafenib (right).  
 As the development of new natural products as therapeutics moves into the 
future, traditional methodologies have continued to evolve, including new isolation and 
characterization techniques, and new and unique sources of chemodiversity. 
Established natural products have served as the inspiration for synthetic drugs, but 
have also found new life in conjunction with other therapeutic methods. Paclitaxel, in 
particular, has been at the forefront of combining natural products with nanoparticles. 
Nanoparticular paclitaxel, in various forms, has been approved as a treatment as 
recently as 2014, with the nanoparticle serving to increase the delivery and 
effectiveness of the natural product.41 Similarly, there is a growing interest in natural 
products serving as the building blocks or scaffolds for larger, synthetic molecules that 
have drug efficacy.42 By far the most persistent challenge of natural product drug 
discovery is simply finding natural product resources. Microorganisms may be easy to 
culture, but inciting diverse chemistry can be difficult, leading to new efforts to physically 
induce new and unique chemistry through culture and growth conditions.46,47 While 
much natural product research, and indeed most of the examples already discussed, 
are from terrestrial organisms, the marine world contains the largest, and largely 
untapped, wealth of biodiversity, and is already well known as a source of new, novel 
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chemodiversity.48 Finding new sources of chemodiversity, and evolving new techniques 
to aid in compound development, remain critical to the continued success of natural 
product therapeutics. 
1.3. Marine Derived Therapeutics 
 While terrestrial sources have undoubtedly been the major focus of most natural 
products research, the marine environment holds the wealth of biodiversity on the 
planet. The oceans cover approximately 70% of the Earth’s surface, with over half of the 
total animal phyla described being fully or partially marine-dwelling.49 The knowledge of 
marine-derived chemistry is certainly prominent throughout history: many cultures relied 
on marine sources for herbal remedies and cuisine, most famously puffer fish (Fugu) 
used in Japanese cuisine, and “Tyrian Purple” dye from Mediterranean mollusks being 
used both as a dye and as a remedy for leukemia. Marine natural products research 
has lagged behind terrestrial counterparts largely due to the difficulty of collection of 
organisms, and though sporadic reports of marine-derived chemistry have occurred 
throughout the last several centuries, marine natural product research didn’t flourish 
until much more recently.48  
Marine natural products play an important role in the therapeutics industry, with 
several FDA approved agents being derived from marine sources. The impetus of 
marine drug discovery research began with the isolation of several bioactive arabinose-
containing nucleosides from a Caribbean sponge Tethya crypta. These compounds 
were groundbreaking, as they were bioactive without a deoxyribose or sugar moiety, 
which was viewed as requirements for bioactivity at the time.50 These compounds led to 
the development of marine derived, semi-synthetic FDA approved drugs such as 
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cytosine arabinoside (Ara-C), an anti-tumor agent, and adenine arabinoside (Ara-A), an 
antiviral agent. Most recently, Adcetris® was approved by the FDA in 2014 against 
various kinds of leukemia. Adcetris® is an antibody-drug conjugate, the scaffold of 
which is based on the dolastatins, cyclic and linear peptides isolated from sea hare 
Dolabella auricularia.48 There are also myriad marine-derived drug agents throughout 
the clinical pipeline, representing a large range of chemical classes and disease fields 
(Table 1.1.), demonstrating the diversity of chemistry and biological activity present in 
the marine environment.48,51  
Table 1.1. Selected natural product and natural product derivatives that are FDA-Approved agents or 
within the clinical pipeline.51 
Clinical 
Status 
Compound 
Name 
Source 
Organism 
Chemical Class Disease Area 
FDA 
Approved  
Cytarabine  
(Ara-C) 
Sponge Nucleoside Cancer 
FDA 
Approved 
Vidarabine  
(Ara-A) 
Sponge Nucleoside Antiviral 
FDA 
Approved 
Ziconotide Cone Snail Peptide Pain 
FDA 
Approved 
Eribulin 
Mesylate 
(E7389) 
Sponge Polyketide Hypertriglyceridermia 
FDA 
Approved 
Trabectedin 
(ET-743) 
Tunicate Alkaloid Cancer 
FDA 
Approved 
Brentuximab 
vedotin (SGN-
35) 
Mollusk Antibody-drug 
conjugate 
Cancer 
Phase III Tetrodotoxin Unidentified 
Microorganism 
Glycoside Pain 
Phase III Plitidepsin 
(Aplidine) 
Tunicate Cyclic depsipeptide Cancer 
Phase II DMXBA (GTS-
21) 
Worm Alkaloid Cognition, 
Schizophrenia 
Phase II Plinabulin (NPI 
2358) 
Fungus Diketopiperazine Cancer 
Phase I Bryostatin 1 Bryozoan Polyketide Cancer, Alzheimer’s 
Phase I Pseudopterosins Soft Coral Diterpene glycoside Wound Healing 
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1.4. Summary and Research Objectives 
Secondary metabolism, though unessential for life, plays a critical role in the lifespan of 
many organisms on Earth. The chemical properties of these secondary metabolites 
have been exploited throughout mankind’s existence, and in modern times, much of the 
advancements in treating disease is owed to natural products chemistry. Though 
interest in traditional natural products research has waxed and waned over the years, 
the chemical potential present in nature is undoubtable, and while much of the terrestrial 
world has been mined as chemodiversity sources, the marine environment has largely 
lagged behind. However, the marine environment, with its larger degree of biological 
and chemical diversity, continues to serve as a source of new chemistry in the ongoing 
fight against human pathogens.  
As the search for new, biologically active chemistry continues, it is key to search 
for unique biodiversity, and utilize cutting edge techniques to make discovery and 
isolation of new compounds more efficient. The following chapters seek to do that, by 
mining both marine mangrove-associated fungi, and cold water sponges for new 
chemistry, and utilizing advanced mass spectrometric techniques to guide dereplication 
and structural elucidation.  
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CHAPTER TWO: 
MINING FLORIDIAN MANGROVE ENDOPHYTIC FUNGI FOR ANTI-INFECTIVES 
 
2.1. The Hunt for Antibiotics 
2.1.1. The ESKAPE Pathogens 
One of the greatest challenges facing human health in the modern world is the 
rise of pathogenic drug resistance. In particular, antibiotic resistance in bacterial 
pathogens has been on the rise for decades, leading to one of the largest public health 
issues in the developed world. The discovery of penicillin in the 1940s inspired the 
“Golden Age of Antibiotics”, with new and safe antibiotics flooding the market.1 These 
antibiotics represent a great structurally diversity, and inhibit bacterial growth through a 
number of mechanisms, including sodium channel blocking and cell wall disruption, 
among others.2,3 Despite the chemical diversity among marketed drugs, the greater 
genetic flexibility of human pathogens has resulted in the now-predictable development 
of antibiotic resistance. Coupled with the rise of antibiotic resistance was the general 
decline in new market antibiotics. In 2007, the number of newly introduced antibiotics 
was less than half the number almost thirsty years prior (Figure 2.1.).1 The rise of drug 
resistance, and the decline of new drugs to combat disease, has resulted in one of the 
most health prevalent concerns of the modern world. 
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 Figure 2.1. Decline in new antibiotics from 1983-2007.1  
The most prevalent and deadly of antibiotic resistant bacterial pathogens are the 
six ESKAPE pathogens.1 These pathogens, Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, 
and Enterobacter species, represent both gram-positive and gram-negative bacteria, 
are the most common nosocomial bacterial infections, and effectively “escape” the 
effect of antibiotic drugs.4 Chief among the ESKAPE pathogens, methicillin-resistant 
Staphylococcus aureus (MRSA) (Figure 2.2.), represents the largest and most fatal 
bacterial infection in US hospitals. As of 2007, MRSA causes ~18,000 deaths per year,5 
more than both HIV/AIDS and tuberculosis combined,1 with the largest proportion of 
deaths occurring in infant or very old patients, who typically undergo longer hospital 
stays and have more vulnerable immune systems.6 To further complicate the fight 
against bacterial pathogens, many pathogens have developed pan-antibiotic resistance, 
and exist in varied morphological forms, like biofilms and free-living forms, that require 
drugs with different molecular targets.7 Because of their virulence, morphological 
variety, and modes of transmission, the ESKAPE pathogens are some of the most 
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important and intensely studied bacterial pathogens, with national investment in 
research exceeding $800 million annually.4  
 
Figure 2.2. SEM Images of MRSA and vancomycin-resistance Enterococcus faecium (VRE). (A) 
A Scanning-electron microscope (SEM) image of MRSA cell clusters enmeshed with human red blood 
cell. Photo from National Institute of Allergy and Infectious Diseases. (B) Three-dimensional computer 
generated image of VRE cells based on SEM images of bacterial cells, Photo by James Archer, CDC 
Public Health Image Library.  
 
2.1.2. Mangrove Forests 
 Mangrove environments possess a wealth of biological and chemical diversity. 
Mangrove forests exist on the interface of terrestrial and marine systems, and, second 
only to coral reefs, are the largest source of biodiversity in the marine environment.8 No 
small part of the biodiversity in mangrove forests are microbial. Surveys of mangrove 
forests around the globe found hundreds of microbial species, including actinomycetes, 
bacteria, and fungi, with a range of morphologically and ecologically different members 
of each clade.9 The endophytic microbial community can also range from terrestrial 
species in the upper and inland portions of individual mangrove trees, to marine-
exclusive species within the trees nearest and submerged in the water.9 In addition to 
biological stress, mangrove forests face harsh environmental conditions. Mangrove 
forests are considered fringe environments, and environmental conditions like water 
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level, rain fall, temperature, and salinity varying greatly over the course of days or 
hours.10 The resulting ecosystem is environmentally stressful with harsh competition 
within the endophytic microbes, ideal for unique biological and chemical diversity.9 
 The Floridian mangrove forests represent a highly diverse biological system. 
Weather patterns are highly variable across the state, with average rainfall varying from 
45-60 inches per year depending on location, with heavy storm surges dropping up to 9 
inches of rain in a matter of hours. Similarly, the landscape ranges drastically from the 
shallow, clay and limestone based soil in the northern portions of the state to swampy, 
highly acidic environments in the southern Everglades and surrounding areas.10 These 
variable conditions make for a diversity of micro-ecosystems within the total mangrove 
forests found along the Gulf of Mexico, and is reflected in the flora and fauna of the 
forests.  
 
Figure 2.3. Floridian mangrove species. Red mangroves (A) with aerial prop roots, black 
mangroves (B) with pneumatophores emerging from the soil, and white mangrove leaves (C). 
Photo: Cathleen Bester, Florida Museum. 
 
Generally, Floridian mangroves are dominated by red mangroves (Rhizophora mangle), 
noticeable for their aerial prop roots, and black mangroves (Avicennia germinas), which 
produce pneumatophores, modified roots that allow oxygen exchange even when 
mostly submerged in water. A less common species, the white mangrove (Laguncularia 
racemose) is also present in many Floridian forests, and are the most morphologically 
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diverse of the three mangrove species (Figure 2.3.). In addition to mangrove, many 
associated flora species, including buttonwood (Conocarpus erectus) and leatherferns 
(Acrostichum sp.), as well as myriad insect predators.11 The Floridian mangrove forests 
contain a wealth of biological diversity, and a particularly varied and harsh competitive 
environment for microbial species.  
 2.1.3. Exploring Fungal Endophyte Chemistry 
 Mangrove forests, and specifically their endophytic microbial communities, have 
been well studied as sources of new, bioactive chemistry. Compounds produced by 
mangrove fungal endophytes are structurally diverse, including polyketides, terpenes, 
peptides, and quinine derivatives to name a few.12 The chemistry from mangrove fungal 
endophytes exhibits biological activity against a range of disease targets. Most 
prominent are antimicrobial compounds, including antifungals13 and antibiotics.14 They 
have also been a source of anti-parasitic compounds, including compounds active 
against the malarial parasite,15 and feeding deterrents against parasites and insect 
larvae that feed on the mangroves trees.16,17 There have also been several compounds 
isolated with biological activity in various cancer-related bioassays, including cancer cell 
lines, carcinomas, and angiogenesis.17,18  
 One of the largest challenges in culturing fungal endophytes in the lab is 
maintaining the biosynthesis of secondary metabolites. In nature, many biologically 
active secondary metabolites are produced to repel microbial competitors. When 
isolated in the lab, endophytic fungi have little need to produce antibiotic compounds, 
and so production is downregulated or halted altogether.19 The ability to reactivate these 
silent pathways, and to activate biosynthetic gene clusters that may be latent even in 
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nature, are critical to accessing the full wealth of chemical diversity that endophytic fungi 
are capable of producing.  
Historically, activation of these biosynthetic pathways has been achieved by 
molecular targeting, or by cultivation-based techniques.19 Molecular targeting takes 
advantage of the advances in whole-genome sequencing, by identifying and cloning 
secondary metabolism gene clusters into host organisms. This research has resulted in 
several new compounds being identified from even exhaustively studied strains like 
Streptomyces sp., including aspoquinoline A and B (Figure 2.4.).20 Cultivation-based 
techniques can include introducing environmental stressors and novel media types 
during culture to activate secondary metabolic pathways,21,22 or introducing the target 
organism to co-culturing with another microorganism. The presence of a bacterial 
pathogen has been shown to elicit the biosynthesis of otherwise down-regulated 
secondary metabolites, as demonstrated with the discovery of pestalone from a fungal-
bacterial co-culture (Figure 2.4.).23 Despite the success of both techniques, they each 
come with drawbacks. Molecular targeting approaches are hindered by the difficulty in 
identifying and replicating secondary metabolic gene clusters, while culture-based 
methods can be time-intensive while being highly variable in their success rate.19                      
                
 
Figure 2.4. Chemical structures of aspoquinoline A, pestalone, and tenuipyrone. Aspoquinoline A 
(left) was discovered using molecular targeting approaches, pestalone (center) using fungal-
bacterial co-culturing, and tenipyrone (right) using small molecule epigenetic modulators.    
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Epigenetic modulation has appeared as a highly successful method of inciting 
silent secondary metabolic pathways in laboratory culture conditions. Whole-genome 
sequencing of fungi has shown that many secondary metabolic gene clusters occur in 
distal regions of the genome where gene transcription is controlled epigenetically 
through processes like histone deacetylation and DNA methylation.19 Williams and 
colleagues first described utilizing small molecule epigenetic modulators in fungal 
culturing to alter the epigenetic transcription of these gene clusters, resulting in an 
upregulation of secondary metabolites by the pure fungal isolates.19 This work was 
significant because it allowed isolated fungal strains to be grown in simple, fast culture 
conditions, while still producing higher concentrations of new secondary metabolites. 
This methodology has since become significant in fungal natural products research, 
yielding many new compounds with anti-infective biological activity.24,25  
 
Figure 2.5. Comparison of methods to activate silent fungal biosynthetic gene clusters (BGC). (A) 
Example of co-culture between a fungal and bacterial isolate. (B) Identification, cloning, and 
expression of fungal gene clusters in a host organism. (C) Activation of BGC in epigenome using 
small molecule epigenetic modulators. Activated BGC results in the biosynthesis of secondary 
metabolites.26      
 
 
32 
 
2.2. Research Objectives 
 In the face of rising drug resistant bacterial pathogens, a need for new sources of 
bioactive chemistry is paramount. Mangrove systems represent harsh and competitive 
environments, particularly for the endophytic microorganisms. While fungal endophytes 
in mangroves have been proven to be great chemodiversity sources, the vast majority 
of research has been conducted on Asian, Indian, and Indo-Pacific mangrove forests. 
Floridian mangrove forests, conversely, are virtually untapped for their biological and 
chemical diversity. In order to access the wealth of chemical potential present in these 
systems, we here report the collection and isolation of Floridian mangrove endophytic 
fungi, and a high-throughput screening (HTS) of their extracts against the ESKAPE 
pathogens. In order to effectively access these fungi’s full biosynthetic potential, small 
molecule epigenetic modifiers were utilized in culture conditions. Following this HTS, 
select fungi with potent activity against one or more of the ESKAPE pathogens were 
grown in large scale and studied for their bioactive chemistry.  
2.3. High-Throughput Screening of Epigenetically Modulated Mangrove 
Endophytes 
2.3.1. Collection and Isolation of Fungal Strains 
 Mangrove tissues were collected in the field in various microclimates throughout 
Florida. Collection sites ranged from urban areas, remote locations in the Florida 
Everglades, and in and around the islands of the Florida Keys (Table 2.1., Figure 2.6.). 
Tissue was collected from stem, roots, bark, and leaves of all three types of Floridian 
mangroves (R. mangle, A. germinas, and L. racemose), as well as mangrove 
associated flora (C. erectus) and marine sediment in the mangrove forests.
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Table 2.1. Collection Sites from Florida 
Mangrove Forests  
Collection  
Site 
Code 
Name 
Everglades 
National Park 
(2010) 
EG10 
Courtney Campbell 
Causeway 
(Tampa, FL) 2010 
CC10 
CQ (2010) CQ10 
Everglades 
National Park 
(2012) 
EG12 
Keys Marine Lab 
(2012) 
KML12 
Howard-Franklin 
Bridge 
(Tampa, FL) 2014 
HF14 
Keys Marine Lab 
(2014) 
KML14 
 
Figure 2.6. Map of Florida collection sites. 
©GoogleEarth 
 
Procedures for collection of mangrove tissue and isolation of fungal strains have 
been previously established in our lab to maximize growth of hardy fungal endophytes 
(Appendix I).24,27 Briefly, mangrove tissue is surface-sterilized in the field, and portions 
of tissue are embedded in various types of solid, selective the growth media. Growth 
media vary in carbohydrate source (dextrose, glycerol, potato dextrose, actinomycete 
agar) and presence of antibiotics and antifungals (chloramphenicol, cycloheximide, 
nystatin) to discourage the growth of prolific fungal strains and encourage the growth of 
slower, hardier fungal strains. Pure fungal strains are obtained after iterative rounds of 
isolation, and fungal isolates are frozen in glycerol for long-term storage.  
2.3.2. Culture, Extraction, and Screening of Fungal Isolates 
After isolation, fungal isolates were grown in small scale and extracted. 
Procedures for the growth and extraction of fungal isolates was developed in our lab,24 
and were adapted for HTS of thousands of fungal isolates. In addition to non-
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modulated, “control” growth conditions, each isolate was also grown in the presence of 
one of two small molecule epigenetic modulators. Sodium butyrate, a histone 
deactylase inhibitor (HDACi), and 5-azacytidine, a DNA methyl transferase inhibitor 
(DNMTi) were selected as modulators due to their cost and reported use in literature 
(Figure 2.7).19,24 For each growth condition, several portions of the fungal mat were 
submerged in an untreated dextrose broth, or a dextrose broth containing the HDACi or 
DNMTi modulator, and transferred onto unprocessed rice.  
 
 Figure 2.7. Chemical structures of sodium butyrate (left) and 5-azacytidine (right).  
 
Fungal cultures were incubated for 21 days, and extracted with ethyl acetate (EtOAc). 
Extracts were dried down and solvated in dimethyl sulfoxide (DMSO) at 5 mg/mL. A 
portion of each extract was frozen and stored for long-term use, while a 150 µL aliquot 
of each extract was plated for biological testing against the ESKAPE pathogens.  
2.3.3. Results of High-Throughput Screening 
Over the course of the two year HTS of mangrove fungal endophytes, 
approximately 2700 fungal isolates were collected from several mangrove forests 
throughout Florida. When cultured in the epigenetically modulated or unmodulated 
growth conditions, they produced 8000 distinct fungal extracts. In a screen for biological 
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activity against the ESKAPE pathogens, 578 extracts displayed activity, a 7.5% activity 
rate for our whole fungal library. This activity rate is in a desirable range for a HTS of 
similar size, indicating that extraction and biological screening did not produce an 
overabundance of falsely positive results. Of the 578 active samples, untreated, 
“control” growth conditions accounted for 191 extracts (~33%), while HDACi and DNMTi 
treated growth conditions accounted for 169 (~29%) and 218 (~37%) of the active 
extracts, respectively. Altogether, the addition of epigenetic modulators resulted in an 
additional 20% increase in the activity rate when compared to control-only activity rate 
(Figure 2.8.). Biological activity of the extracts was diverse, with activity against all six 
of the ESKAPE pathogens present, most commonly S. aureus, and at a range of 
effective concentrations.  
 
Figure 2.8. Activity rate of HTS of mangrove fungal endophytes. (A) Of the ~8000 extracts 
screened, 7.5% displayed biological activity. (B) Of the ~600 active samples, ~33% were active in 
at least the control growth treatment while epigenetic modulation accounts for ~30% and ~37% of 
total active extracts. 
 
Epigenetic modulation markedly improved the biological activity of the extract 
library (Figure 2.9.). Of the 578 active extracts, 191 were active in only the control 
growth culture, while 101 were active in only the epigenetically modulated growth 
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conditions. Of the 101 modified-only active extracts, 48 were active in only the HDACi 
growth treatment, and 53 were active in only the DNMTi growth condition. In addition to 
inducing activity, epigenetic modulation also increased the potency of many extracts. Of 
the active extracts, 72 had significantly improved biological activity in only one of the 
modified growth conditions. 
 
Figure 2.9. Effects of epigenetic modulation on biological activity. (A) Epigenetic modulation 
induced biological activity in ~100 fungal isolates. Of these, 48 were in the HDACi treatment, and 
53 were in the DNMTi treatment. (B) In 72 fungal isolates, epigenetic modulation increased the 
potency compared to the control growth treatment, with increase in activity evenly distributed 
between modified treatments.  
 
Screening of the fungal extract library showed a strong source of biologically 
active extracts against the six ESKAPE pathogens. Introduction of epigenetic 
modulators significantly increased the diversity and potency of the fungal extract library. 
The resulting library represents a robust library of extracts that can be studied for their 
chemistry.  
2.4. Chemical Investigation of Phomasetin sp. and Alternia sp. Fungal Isolates 
2.4.1. Selection and Growth of Select Fungal Isolates 
Following HTS of our fungal endophyte library, select fungi were prioritized to be 
grown in large-scale culture and studied for their chemistry. Prioritization was based on 
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the potency and selectively relative to the rest of the extract library. From the list of 
prioritized fungi, two, KML14-75MG-C8 and HF14-17C-3B, were selected for further 
study. The former, isolated from the leaf of an exotic Australian mangrove relative, 
Pandanus spiralis, collected in the Fairchild Botanical Gardens in Miami, FL, showed 
highly potent activity against S. aureus (IC50= 1 µg/mL) in all three culture conditions. 
The latter fungus was isolated form the leaf of a red mangrove (R. mangle) in Tampa, 
FL, and showed selective activity against S. aureus (IC50=10 µg/mL) in the DNMTi 
growth culture.  
Fungal isolates were re-grown in large scale to facilitate chemical investigation. A 
larger selection of fungal biomass was grown in a larger volume of rice media and 
epigenetic modulation broth, representing a ten-fold increase in scale compared to the 
HTS culture conditions. Fungal cultures were incubated for 21 days, before extraction 
for 24 hr in a 1:3 methanol (MeOH): ethyl acetate (EtOAc) mixture. Following this first 
extraction period, the fungi were extracted with EtOAc for two more 24 hr periods. 
Biological activity was verified in the crude extracts before they were subjected to 
chromatographic separation guided by biological activity. 
2.4.2. Isolation and Characterization of Equisetin and Ent-equisetin 
The crude extracts of all three culture treatments of KML14-75MG-C8 were first 
partitioned between EtOAc and a 1:3 MeOH:H2O layer. The EtOAc layers were then 
subjected to Medium Pressure Liquid Chromatography (MPLC) to yield ~7 fractions. 
While several of these fractions were active against S. aureus, each extract had a single 
fraction that maintained the potent activity (1 μg/mL) desired. A Liquid 
Chromatography/Mass Spectrometry (LC/MS) analysis of these fractions revealed a 
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nearly identical chemical profile between all three treatments, and so the active MPLC 
fractions were combined and carried forward to further separation with High 
Performance Liquid Chromatography (HPLC). Biological activity was used to guide 
initial normal phase (NP) HPLC with Hexanes and EtOAc. After NP HPLC, reverse 
phase (RP) HPLC with water and acetonitrile (ACN) was used to purify two closely 
eluting compounds, labeled MAK 5 and MAK 7 (Scheme 2.1).  
Proton Nuclear Magnetic Resonance (1H NMR) spectroscopy revealed nearly 
identical spectra for MAK 5 and 7, while High Resolution Electrospray Ionization Mass 
Spectrometry (HRESIMS) revealed the same mass for each compound (m/z 374.4940 
[M+H]+, m/z 374.4940 [M+H]+), matching the literature value of two diastereomers, 
equisetin (1) and ent-equisetin (2) (Figure 2.10.), two potent cytotoxins isolated 
exclusively from Phomatsetin sp.28 A full 2D NMR data set was obtained for each 
compound in order to verify the identities of each compound.  
 
Figure 2.10. Chemical structures of equisetin (1) and ent-equisetin (2). Important COSY (bold) 
and HMBC (arrow) correlations used to verify the structures are shown.  
39 
 
Table 2.2. shows the 1H and 13C NMR data for MAK 5 and MAK 7 in comparison 
to 1 and 2. Prominent in each were several methyl groups, two olefinic protons, and 
protons on a nitrogen-bearing methyl (δH 3.05). Long-range 2D NMR data (HMBC, 
COSY) were used to construct and connect spin systems within the molecule (Figure 
2.10). Both 1 and 2 notably contained a tetramic acid substructure, with the nitrogen-
bearing methyl correlating to two carbonyls (δC 177.0 and 200.2), as well as an alkyl 
chain terminating in a primary alcohol, indicated by the proton and carbon chemical 
shifts of positions 5’, 6’, and 6’’. Additionally, a decalin ring system was determined, 
containing a endo-cyclic alkene at position 4 and 5, and a trans- exo-cyclic alkene at 
position 3. There were no significant long-range correlations between the two portions 
of these substructures, however, both correlated to quaternary carbons at position 1 
and 3’. While position 1 had a chemical shift indicative of a fully substituted alkene (δC 
100.0), position 3’ had a significantly higher chemical shift (δC 200.7), which, together 
with HRESIMS data, confirmed the presence of an enol alkene connecting the tetramic 
acid and decalin portions of the molecule. Stereochemistry of both was determined by 
comparison of J-coupling constants at key positions to literature values of synthetic 
equisetin and ent-equisetin.28 The J-coupling constants at positions 3, 4, 5’, 6’, 6’’, and 
7’’ indicated that MAK 5 was equisetin (1), while MAK 7 was ent-equisetin (2), 
differentiated by the stereochemistry of substituents around the decalin ring system.  
After purification and structural verification of 1 and 2, a final round of biological 
assay found the compounds to be active against S. aureus at 1 μg/mL (2.67 µM) and 10 
μg/mL (26.70 µM), respectively. However, both compounds are reported in the literature 
as known cytotoxins. 
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Table 2.2. 1D NMR data for MAK 5, MAK 6, equisetin, and ent-equisetin in CDCl3. 
Pos δC
b δH (m, J(Hz))
a δC
b δH (m, J(Hz))
a δC
b δH (m, J(Hz))
a δC
b δH (m, J(Hz))
a 
  MAK 5   Equisetin   MAK 7   Ent-Equisetin   
1 190.7 ---      190.6 ---     190.7 ---       190.7 ---       
2 48.8 ---      48.4 ---      500.0 ---       48.0 ---       
3e 45.0 3.32 (br s, 1 H) 44.6 3.32 (br d, 1 H) 45.0 3.35 (br s, 1 H) 44.6 3.36 (br s, 1 H) 
4 126.6 or 129.9 5.40 (br s, 1 H) 127.1 or 126.2 5.40 (br s, 1 H) 126.6 or 129.9 5.40 (br s, 1 H) 
127.1 or 
126.2 5.42 (m, 1 H) 
5 126.6 or 129.9 5.40 (br s, 1 H) 130.4 or 129.8 5.40 (br s, 1 H) 126.6 or 129.9 5.42 (br s, 1 H) 
130.4 or 
129.8 5.41 (m, 1 H) 
6a 38.6 1.83 (m, 1 H) 38.4 1.84 (br t, 8.0, 1 H) 38.5 1.83 (m, 1 H) 38.5 1.83 (m, 1 H) 
7a 42.2 0.90 (m, 1 H) 41.9 0.90 (q, 12.0, 3 H) 42.0 0.89 (m, 1 H) 42.0 0.90 (q, 12.0, 3 H) 
7e  1.79 (m, 1 H)  1.81 (br d, 12.0, 1 H)  1.79 (m, 1 H)  1.80 (m, 1 H) 
8a 33.5 1.52 (m, 1 H) 33.3 1.48 (m. 1 H) 33.5 1.52 (m, 1 H) 33.3 1.48 (m, 1 H) 
9a  35.7 1.09 (q, 9.5, 1 H) 35.5 1.11 (q, 9.0, 1 H) 35.7 1.09 (q, 9.5, 1 H) 35.6 1.11 (q, 12.0, 1 H) 
9e  1.75 (br m, 1 H)  1.76 (br m, 1 H)  1.75 (br m, 1 H)  1.77 (br m, 1 H) 
10a 28.4 1.09 (q, 12.0, 1 H) 28.1 1.04 (q, 12.0, 1 H) 28.1 1.09 (q, 12.0, 1 H) 28.0 1.04 (m, 1 H) 
10e  1.97 (br m, 1 H)  1.96 (br d, 12.0, 1 H)  1.97 (br m, 1 H)  1.96 (br m, 1 H) 
11a 40.0 1.69 (br s, 1 H) 39.6 1.66 (br t, 11.0, 1 H) 40.0 1.69 (br s, 1 H) 39.9 1.66 (m, 1 H) 
12 14.3 1.47 (br s, 3 H) 13.7 1.46 (s, 3 H) 14.5 1.47 (br s, 3 H) 14.0 1.45 (s, 3 H) 
13 130.8 5.17 (m, 1 H) 130.4 or 129.8 5.17 (dd, 15.0, 9.0, 1 H) 131.0 5.17 (m, 1 H) 
130.4 or 
129.8 
5.16 (dd, 15.0, 9.0 1 
H) 
14 127.0 5.25 (m, 1 H) 127.1 or 126.2 5.25 (dq, 15, 6.5, 1 H) 127.0 5.25 (m, 1 H) 
127.1 or 
126.2 
5.24 (dq, 15.0, 6.0, 1 
H) 
15 17.8 1.52 (d, 5.0, 3 H) 18.2 1.56 (d, 6.5, 3 H) 17.8 1.52 (d, 5.0, 3 H) 18.2 1.56 (d, 6.5, 3 H) 
16 22.5 0.92 (d, 6.5, 3 H) 22.5 0.92 (d, 6.5, 3 H) 22.5 0.92 (d, 6.5, 3 H) 22.6 0.92 (d, 6.5, 3 H) 
2' 177.0 ---       176.7 ---       177.0 ---    176.8 ---       
3' 100.0 ---       99.8 ---       100.1 ---       100.0 ---       
4' 200.2 ---       198.8 ---       200.0 ---       198.8 ---       
5' 66.1 3.67 (br t, 5.0, 1 H) 66.4 3.67 (dd, 5.0, 3.0, 1 H) 66.0 3.65 (br t, 3.5, 1 H) 66.6 3.66 (t, 3.5, 1 H) 
6' 60.3 
4.07 (br d, 11.0, 1 
H) 60.0 4.07 (dd, 11.0, 3.5, 1 H) 60.5 4.05 (br d, 11.0, 1 H) 60.0 
4.05 (dd, 11.0, 3.0, 1 
H) 
6''  
3.9 (dd, 11.4, 5.0, 1 
H)  
3.90 (dd, 12.0, 5.0, , 1 
H)  
3.83 (dd, 12.0, 3.0, 1 
H)  
3.85 (dd, 12.0, 3.5, 1 
H) 
7' 27.2 3.06 (s, 3 H) 27.2 3.07 (s, 3 H) 27.2 3.04 (s, 3 H) 27.0 3.05 (s, ,3 H) 
enol H  --- ---  ---  17.3 (s, 1 H)  --- ---  ---  17.3 (s, 1 H) 
 a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration); b  13C recorded at 125 MHZ.
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 Scheme 2.1. Isolation of MAK 5 and MAK 6. 
 
2.4.3. Isolation and Characterization of Alternaria sp. Metabolites 
The second fungus selected for chemical investigation, HF14-17C-3B was grown 
in large scale identically to KML14-75MG-C8, but only in the DNMTi growth treatment. 
Following a partition between EtOAc and 1:3 H2O:MeOH, the EtOAc layer was 
subjected to NP MPLC to yield eight fractions. Two fractions showed activity against S. 
aureus; the first (G) was active at 10 μg/mL, while the second (H) was active at         
100 µg/mL. Initial separation of both fractions was performed with RP HPLC with H2O 
and MeOH. Following a final round of purification with H2O and ACN, two compounds 
(MAK 9, MAK 10) were isolated from fraction G, while a third (MAK 11) was isolated 
from fraction H (Scheme 2.2).  
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 Scheme 2.2. Isolation of MAK 9, 10, and 11. 
 
MAK 9 displayed several 1H and 13C NMR signals similar to 1 and 2, in particular 
the ketone (δC 179.8 and 191.8) and enol (δC 99.9 and 198.9) carbon signals, and 
signals in the olefinic region (Table 2.3.). Noticeably absent, however, was the nitrogen-
bearing methyl present in 1 and 2, and MAK 9 displayed an additional two olefins. 
HRESIMS for MAK 9 (m/z 400.5231  [M+H]+) matched altersetin (3),29 a compound 
structurally similar to 1 and 2. 2D NMR was used to confirm the structure of MAK 9. 
Similar to 1 and 2, MAK 9 also has a tetramic acid portion, though containing a 
secondary amide and alcohol. Long-range HMBC correlations between the protons of 
the alcohol side-chain and the 2’ and 4’ position carbonyls verified the tetramic acid. 
The decalin ring portion was largely confirmed by COSY correlations. Noticeably, there 
is a conjugated exo-cyclic trans alkene system connected to the decalin ring at position 
3. The confirmation of the conjugated system was confirmed to match that of 3 based 
on the J-coupling constants of the alkene protons.  
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Table 2.3. 1D NMR data for MAK 9 and altersetin (3) in DMSO-d6.29 
Pos δCb δH (m, J(Hz))a δCc δH (m, J(Hz))a 
  MAK 9   Altersetin   
NH --- 9.22 (br s, 1 H) ---    9.20 (br s, 1 H) 
2 182.8 --- 179.8 --- 
3 100.0 --- 99.7 --- 
4 191.5 --- 191.5 --- 
5 66.9 3.60 (br s, 1 H) 66.8 3.61 (br s, 1 H) 
6 199.1 --- 198.6 --- 
7 45.5 --- 48.6 --- 
8 39.1 1.55 (m, 1 H) 39.0 1.56 (m, 1 H) 
9a 28.0 1.89 (m, 1 H) 27.9 1.90 (m, 1 H) 
9e       1.03 (m, 1 H)       1.03 (m, 1 H) 
10a 36.0 0.99 (m, 1 H) 35.6 1.00 (m, 1 H) 
10e       1.72 (m, 1 H)       1.70 (m, 1 H) 
11 33.0 1.51 (m, 1 H) 33.1 1.50 (m, 1 H) 
12a 42.0 0.82 (m, 1 H) 42.0 0.80 (m, 1 H) 
12e       1.82 (m, 1 H)       1.80 (m, 1 H) 
13 38.0 1.80 (m, 1 H) 38.4 1.80 (m, 1 H) 
14 131.0 5.45 (m, 1 H) 130.6 5.45 (dm, 1 H) 
15 126.2 5.36 (m,, 1 H) 126.2 5.35 (m,, 1 H) 
16 45.5 3.43 (m, 1 H) 44.2 3.45 (m, 1 H) 
17 130.0 
5.24 (dd, 14.0, 4.0, 1 
H) 131.1 
5.24 (dd, 14.0, 3.5, 1 
H) 
18 131.5 
5.71 (dd, 10.9, 3.0, 1 
H) 131.6 
5.70 (dd, 10.9, 3.5, 1 
H) 
19 131.5 
5.88 (dd, 11.0, 3.0, 1 
H) 131.6 
5.90 (dd, 10.9, 3.3, 1 
H) 
20 128.5 
5.50 (dq, 15.2, 5.5, 1 
H) 128.3 
5.50 (dq, 15.4,  6.0, 1 
H) 
21 18.9 1.64 (d, 6.7, 3 H) 18.1 1.64 (d, 6.7, 3 H) 
22 14.0 1.35 (s, 3 H) 13.8 1.35 (s, 3 H) 
23 22.7 0.86 (d, 7.0, 3 H) 22.7 0.85 (d, 6.7, 3 H) 
24 21.1 3.90 (m, 1 H) 21.0 3.91 (m, 1 H) 
25 66.1 1.20 (d, 6.0, 3 H) 65.9 1.17 (d, 6.3, 3 H) 
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling in Hz, integration). b 13C 
recorded at 125 MHz. 
 
HMBC correlations linked the two portions of the molecule via an enol identically to 1 
and 2, thus confirming the structure of MAK 9 to be altersetin (3) (Figure 2.11.). 
Relative stereochemistry was confirmed based on the 1H NMR shift and J-coupling 
values of positions 3, 4, 5’, 6’, 6’’ ,and 7’’ as compared to literature values.29  
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Figure 2.11. Chemical Structures of altersetin (3), altertoxin I (4), and pyrophen (5). Important 
COSY (bold) and HMBC (arrow) correlations are shown.  
 
A second compound, MAK 10, was isolated in a similar method to compound 3. It 
was structurally very different from previously isolated compounds, with the 1D NMR 
spectra indicating the presence of multiple ketones and phenolic protons (Table 2.4.). 
The HRESIMS for MAK 10 (m/z 353.3433 [M+H]+) matched that of altertoxin I (4),30 a 
toxin isolated from strains of Alternaria sp., the same genus that produces 3. The 
HRESIMS for MAK 10 displayed a prominent base peak (m/z 317.3424 [M+H-2H2O]+) 
indicative of a dehydration of the secondary and tertiary alcohols present in 4, which 
generates an additional aromatic ring in the resulting fragment. The structure of MAK 10 
was verified by 2D NMR (COSY, HMBC). Long-rage HMBC correlations indicated that 
the two aromatic rings were connected to one another, and that each was adjacent to a 
carbonyl carbon. The chemical shift of the phenolic protons (δH 12.34 and 12.69) 
indicated that they are located in the β-position to the carbonyls (δC 202.0, 204.9) and 
are capable of hydrogen bonding. COSY correlations indicated a spin system of an alkyl 
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chain bridging the two carbonyl, with a secondary and tertiary alcohol present (Figure 
2.11.). The spectroscopic data verified the structure of MAK 10 to be identical to 
altertoxin I(4). 
Table 2.4. 1D NMR data for MAK 11 and altertoxin I (3).30  
Pos δCc δH (m, J(Hz))a δCb δH (m, J(Hz))a 
  MAK 11   Altertoxin   
1 132.6 7.83 (d, 8.7, 1 H)) 132.7 7.87 (d, 8.8, 1 H) 
2 120.0 7.07 (d, 8.8, 1 H) 119.5 7.01 (d, 8.8, 1 H) 
3 162.3 ---  162.3 ---     
3a 116.9 ---      116.9 ---      
4 204.9 ---       205.0 ---     
5e 33.9 2.69 (dt, 16.7, 3.1, 1 H) 34.0 2.65 (dt, 15.0, 3.0, 1 H) 
5a  3.17 (m, 1 H)  3.17 (m, 1 H) 
6a 34.4 2.43 (td, 14.3, 4.1, 1 H) 34.5 2.43 (dt, 13.0, 3.0, 1 H) 
6e  3.01 (m, 1 H)  3.17 (m, 1 H) 
6a 69.2 ---      69.2 ---      
6b 51.9 3.07 (d, 5.5, 1 H) 51.9 3.09 (d, 9.0, 1 H) 
7 66.1 4.76 (m, 1 H) 66.1 4.78 (ddd, 12.0. 9.0, 5.0, 1 H) 
8a 47.7 2.91 (dd, 16.1, 12.0, 1 H) 47.7 2.94 (dd, 16.0, 5.0, 1 H) 
8e  3.08 (m, 1 H)  3.07 (dd, 16.0, 4.0, 1 H 
9 202.0 ---       202.0 ---    
9a 116.1 ---       117.4 ---   
9b 139.1 ---     139.1 ---    
10 162.0 ---     162.0 ---     
11 117.6 7.02 (d, 8.8, 1 H) 117.5 6.92 (d, 8.8, 1 H) 
12 132.4 7.81 (d, 8.7, 1 H) 132.4 7.82 (d, 8.8, 1 H) 
12a 124.4 ---    124.1 ---    
12b 122.7 ---       122.7 ---      
12c 135.4 --- 135.5 ---    
3-OH ---  12.69 (s, 1 H) ---     12.7 (s, 1 H) 
10-OH ---      12.34  (s, 1 H) ---     12.4 (s, 1 H) 
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C 
recorded at 125 MHz. c 13C shifts are taken from HMBC spectrum. 
 
The final compound isolated from HF14-17C-3B was MAK 11. MAK 11 was 
significantly smaller in size than the other compounds isolated from endophytic fungi. 
The 1H NMR spectrum of MAK 11 indicated the presence of two aromatic rings, a 
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methoxy, and a methyl ketone (Table 2.5.). The HRESIMS of MAK 11 (m/z 287.3144 
[M+H]+] matched that of pyrophen (5), an Alterania sp. metabolite.31 The structure of 
MAK 11 was verified using 2D NMR (COSY, HMBC). COSY and HMBC correlations 
indicated two aromatic rings, one singly substituted, connected by a two-carbon alkyl 
chain. The second aromatic ring was heterocyclic, contain an oxygen and an exocyclic 
carbonyl (δC 162.9). The second aromatic ring was determined to contain a m-methoxy 
substituent.  Attached to the alkyl bridge is a secondary methyl amide (Figure 
2.11.).The 2D NMR data verified the base structure of MAK 12, while the relative 
stereochemistry was determined using 1H NMR and optical rotation. Pyrophen, and its 
stereoisomers isopyrophen, vary only in the chirality of position 7. Though the chemical 
shift of the proton at position α is unchanged in both stereoisomers, the shift of the 
amide proton adjacent differs significantly. The amide proton in pyrophen (δH ~6.0) is 
significantly upfield of the amide proton in isopyrophen (δH ~7.0), a difference supported 
by the optical rotation of pyrophen [𝛼]𝐷
25 values of -13.8 for pyrophen and +1.1 for 
isopyrophen.32 The chemical shift of the amide proton (δH 5.96) and optical rotation 
([𝛼]𝐷
25=+1.4) verified MAK 12 as pyrophen (5). 
The three metabolites isolated from HF14-17C-3B have all been previously 
reported from Alternaria sp. Once purified, the compounds were submitted for biological 
activity against the ESKAPE pathogens. MAK 9 was active against S. aureus at 50 
µg/mL (125.24 µM), while MAK 12 was active against S. aureus at 200 µg/mL (696.10 
µM), and MAK 11 was inactive against all six ESKAPE pathogens.  
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Table 2.5. 1D NMR data for MAK 12 and pyrophen (4) in CDCl3.32  
Pos δCc δH (m, J(Hz))a δCb δH (m, J(Hz))a 
 MAK 12  Pyrophen  
1 171.3 --- 169.6 --- 
2 20.9 1.96 (s, 3 H) 23.2 1.96 (s, 3 H) 
NH --- 5.96 (d, 8.5 1H) --- 5.96 (d, 8.4, 1 H) 
α 52.7 5.0 (q, 7.7, 1 H) 52.4 5.0 (dt, 7.9, 7.8, 1H) 
β 38.0 3.09 (d, 7.5, 2H) 38.9 3.08 (d, 7.5 2H) 
2' 162.5 --- 161.3 --- 
3' 100.3 5.74 (d, 2.0, 1 H) 101.2 5.75 (d, 2.2, 1 H)) 
4' 172.0 --- 170.5 --- 
OMe 55.5 3.75 (s, 3 H) 56.0 3.75 (s, 3 H) 
5' 87.7 5.41 (d, 2.1, 1 H) 88.5 5.42 (d, 2.2, 1 H) 
6' 162.9 --- 164.4 --- 
1'' 136.6 --- 135.8 --- 
2'' 129.0 7.12 (m, 1 H) 129.1 7.11 (br d, 6.9, 1 H) 
3'' 128.7 7.25 (m, 1 H) 128.7 7.27 (t, 7.5, 1 H) 
4'' 126.6 7.25 (m, 1 H) 127.2 7.22 (br t, 6.8, 1 H) 
5'' 128.7 7.25 (m, 1 H) 128.7 7.27 (t, 7.5, 1 H) 
6'' 129.0 7.12 (m, 1 H) 129.1 7.11 (br d, 6.9, 1 H) 
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C 
recorded at 125 MHz. c 13C shifts are taken from HMBC spectrum and multiplicity from HSQC 
spetrum. 
 
 
2.5. Summary and Conclusions 
Mangrove forests represent a vast source of microbial bio- and chemodiversity. 
While Asian mangrove forests and their fungal endophyte communities are well-studied 
chemically, the mangrove forests of Florida are virtually untapped for new, bioactive 
chemistry. In order to access this potential, a HTS of mangrove endophytic fungi, 
collected from throughout Florida, were screened against the six ESKAPE pathogens. 
Two small molecule epigenetic modulators were utilized to activate the biosynthetic 
potential of the fungal isolates in the lab.  
Of the 8000 fungal extracts screened, approximately 7.5% percent were 
biologically active against the EKSAPE pathogens, with an additional 20% increase in 
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activity from control growth as a result of epigenetic modulation. Following the success 
of the HTS, select fungal isolates were scaled up and chemically investigated for 
bioactive metabolites. From a Phomasetin sp. fungus, two known cytotoxin 
diastereomers, equisetin and ent-equisetin, were isolated and their structures and 
bioactivity verify. From a strain of Aternaria sp., three known metabolites, altersetin, 
altertoxin I, and pyrophen, were also isolated and their structures and bioactivity 
verified.  
The cultivation and investigation of Floridian mangrove fungal endophytes has 
provided us with a large, robust library of extracts. An initial investigation of highly active 
fungi yielded a number of known metabolites, indicating that earlier, more accurate 
methods of dereplication are needed to more efficiently isolate new chemistry. Despite 
this, the chemical potential of our extract library cannot be understated. The first round 
of fungal isolates intensively studied yielded a number of bioactive metabolites, highly 
diverse in their chemical structure and biological activity. As we continue to screen 
these extracts in new biological assays, and develop more sophisticated dereplication 
techniques, our fungal library will undoubtedly be a valuable source of new, bioactive 
natural products.  
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CHAPTER THREE: 
MASS SPECTROMETRY BASED FUNGAL DEREPLICATION STRATEGIES 
 
3.1. The Need for Dereplication Strategies 
3.1.1. Fungal Natural Products: The Numbers 
 As we enter the new age of chemical research and technology, natural products 
research has never been more productive and prolific.  As recently as 2016, there have 
been over 260,000 natural products reported online,1 more than 50,000 of which are 
marine natural products,2 with an estimated 4,000 new compounds being reported 
every year.3  
Fungi have played a significant role in the history of natural products chemistry: 
they have provided mankind the basis for some of our most important antibiotics, like 
the penicillins and cephalosporins,4 industrial chemicals, and crop and feed additives.5 
Fungi are also the producers of some of nature’s most potent toxins, like the aflatoxins, 
ergot alkaloids, and fusarium toxins (Figure 3.1.).6  In addition to mycotoxins, dozens of 
common nuisance metabolites are known from fungi. Of the fungal genera most 
commonly isolated in the laboratory (Aspergillus, Penicillium, and Fusarium), the 
number of reported compounds can be well into the hundreds or even thousands (1724, 
1726, and 611 compounds, respectively, listed in AntiBase).5 While new methods are 
regularly developed to exploit the greater diversity of fungal chemistry (see Chapter 
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Two), nuisance compounds such as the mycotoxins remain a major obstacle in the 
discovery of new natural products. As this dilemma has become more prevalent, the 
ability to analyze and identify known chemistry (dereplication) has become a critical 
stage of microbial natural products drug discovery.  
              
 Penicillin G    Cefacetril              Aflatoxin B1 
Figure 3.1. Chemical structures of penicillin G, cefacetril, and aflatoxin B1. These compounds are 
representatives of the penicillin, cephalosporin, and aflatoxin compounds classes, respectively.  
 
3.1.2. Tandem Mass Spectrometry in Metabolite Analysis 
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy 
are the two predominate analytical techniques employed for detecting and identifying 
metabolites and small molecules. Consequently, natural product databases are built 
around this spectral data, commonly combined with liquid chromatography (LC) 
separation of crude extracts.7 LC-NMR databases provide powerful tools for structural 
characterization of metabolites,8 which, when combined with chemotaxonomic data,9 
can provide rapid identification of compound scaffolds, and identify new derivatives of a 
compound class. However, NMR experiments are fundamentally more variable than 
their MS counterparts, and NMR-derived database searches can very often produce an 
overabundance of positive results, without accurate and certain identification of new 
metabolites.7 High Resolution MS (HRMS) experiments can be faster and more 
sensitive than their NMR counterparts, but the HRMS data cannot be used to 
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differentiate isomeric compounds, and can similarly produce an overabundance of 
identifications in a database search.8 
Tandem MS (MS/MS or MS2) has emerged as an essential technique for 
structural analysis of biological compounds, including peptides, proteins, and small 
molecule metabolites, and has subsequently formed the basis of most dereplication 
strategies employed in natural products research.10 Tandem MS involves sequential 
ionization of metabolites and fragmentation of the precursor ions.  The resulting 
Tandem MS profile includes both the precursor ion and fragmentation pattern of each 
compound.11 Ionization can occur through any number of ionization techniques 
(electrospray ionization (ESI), fast atom bombardment (FAB), matrix –assisted laser 
desorption/ionization (MALDI). Precursor ions within the ion source are then 
fragmented, and the fragment ions are collectively detected and analyzed (Figure 
3.2.).10  
 
 Figure 3.2. Diagram of Tandem MS experiment.  
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Collision-induced dissociation (CID) is one such fragmentation method. An external 
electrical potential is used to accelerate precursor ions so they collide with neutral 
molecules (helium, nitrogen, argon), inducing fragmentation.12 CID is the mostly 
commonly utilized fragmentation method in Tandem MS experiments: it is easy to 
implement experimentally, the collision energy applied can be varied, resulting in a 
robust fragmentation profile for each metabolite, and it is universally applicable to 
biological analytes.10,12The precursor ion and fragmentation pattern is unique to each 
chemical entity regardless of purity, allowing for accurate differentiation and 
identification of compounds in a complex mixture.  
3.1.3. Benefits and Drawbacks of Tandem MS Databases 
 Tandem MS provides several pieces of data that are highly useful for 
characterization of secondary metabolites. The precursor ion and fragmentation pattern 
of each compound is unique: a single compound can be correctly identified 
independently retention time, purity, and similarity to isomeric compounds.3 While the 
Tandem MS profile for each compound is unique, compounds with similar structures will 
have similar fragmentation patterns. Members of a compound class can be readily 
identified from similarities in fragmentation patterns, and structural determination for 
unreported derivatives can be aided by Tandem MS data (Figure 3.3.).3,5 Tandem MS 
data has often been combined with other data, including chemotaxonomy,9 biological 
activity, and chemical novelty13 to create versatile ad hoc databases for identification of 
known compounds and new metabolites, and for prediction of the biological activity of 
components in crude extracts.  
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 Despite the diverse and detailed public Tandem-MS databases available, there 
are still obstacles to adapting them for use with private extract libraries. In a recent effort 
to dereplicate  ~720 microbial natural product and mycotoxins with UV/vis-MS based 
methods, only 17% of the metabolite profiles overlapped with standards from common 
public databases.14  This low predictive score highlights the inherent problems with 
public databases: variations of experimental parameters and compound datasets can 
produce inconsistent data within databases, or gaps in the data available for each 
compound.3,15  
 
 Figure 3.3. Tandem MS fragmentation patterns of aflatoxin B2, G1, and M1. Different CID 
energies (10mV, blue; 20mV, red; 40mV, green) result in set of fragmentation spectra unique to each 
compound. Similar fragmentation patterns amongst all three are indicative of the fragmentation pattern of 
all aflatoxin compounds. Spectra generated in silico Copyright: METLINTM. 
 
Tandem-MS libraries can be especially prone to absent data, simply because Tandem-
MS spectra are not required for compound publication. Tandem-MS profiles must be 
generated independently5 or with in-silico predictive software.16 With every database, 
the major limitation is that they only identify known chemistry, while new compounds 
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cannot be explicitly identified. Once identified, there is often no specific methodology to 
remove these nuisance compounds to more efficiently access potential new 
chemistry.16 In many cases, public metabolite and mycotoxin databases are combined 
with more customized databases to maximize efficiency with private extract libraries.5,13 
3.2. Research Objectives 
 Fungi have been long been studied for the biologically active chemistry they 
produce. Despite new chemistry being reported from fungal sources every year, fungi 
remain notorious for their nuisance and toxic compounds. As fungal natural products 
research evolves, early identification of these compounds has become imperative. 
Many public and private spectral databases, relying heavily on Tandem MS, have been 
developed to aid in the evaluation of crude extracts and to predict the presence of new 
compounds. While sophisticated, many public databases can be limited in comparison 
to the vast collections of fungal isolates and the nuances of individual instrumentation. 
Tandem MS libraries made for specific, smaller collections of fungal compounds have 
become increasingly effective for analyzing crude extracts for known chemistry.  
 The fungal extract library curated by the Baker lab contains thousands of fungal 
extracts displaying an array of biological activity. Early efforts in our lab to study these 
extracts have been hindered by the large number of mycotoxins and other nuisance 
compounds, identified only after rigorous isolation efforts. In order to create an efficient 
fungal natural product drug discovery program, a two-stage MS-based dereplication 
strategy is herein presented. Dereplication efforts involve the creation of a Tandem-MS 
fungal metabolite database to identify known chemistry in crude extracts with limited 
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work up, and the development of methods to consistently and easily extract toxins from 
crude extracts. Ultimately, new chemistry can be identified and more rapidly isolated.   
3.3. Dereplication Strategy Development and Validation 
3.3.1. Two-Stage Dereplication and Toxin Extraction Protocol 
Our fungal extract library currently contains ~8000 distinct extracts, with many 
displaying biological activity against bacterial pathogens like the ESKAPE pathogens, 
Mycobacterium tuberculosis, and Clostridium difficile, parasite Leishmania sp., 
amoebae Acanthamoeba sp. and Naegleria fowleri, and the Zika virus. However, most 
new compound isolation has been hindered by the large number of mycotoxins present 
in these fungal extracts. In order to more efficiently dereplicate these compounds and 
assess other bioactive components of these extracts, a two-step protocol was 
developed. The first stage involved generating Tandem-MS spectral profiles for each 
bioactive crude extract and screening them against public and in-house fungal 
metabolite and toxin databases, in order to identify known chemistry. Any extracts with 
known or toxic compounds were then subjected to stage two, which involved a mass-
directed separation of the known or toxic compounds from the crude extract. The 
remainder of the toxin-extracted crude extract could then be rescreened for biological 
activity. This two-stage protocol would allow early identification and removal of known 
and toxic compounds from a crude extract, while the rest of the metabolites could be 
evaluated for biological activity and potential new chemistry (Scheme 3.1.). 
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3.3.2. Creation of a Tandem-MS Database for Floridian Mangrove Endophytes 
A standardized experimental protocol utilizing a high resolution Liquid 
Chromatography/ Quadrupole-Time of Flight mass spectrometer (LC/Q-ToF/MS) was 
established for application with all crude fungal extracts.  
 
Scheme 3.1. Metabolite dereplication protocol for crude fungal extracts. Spectrometer images 
courtesy of AgilentTM, https://www.agilent.com  
 
This protocol was specifically designed to minimize preparative steps of the crude 
extract, and allow manual assessment of the crude extract. A test set of fungal extracts 
containing known, previously isolated mycotoxins (KML14-75MG-C8, containing 
equisetin and ent-equisetin; HF14-17C-3B, containing altersetin, altertoxin I, and 
pyrophen) was used to generate and verify this protocol (Figure 3.4.). These extracts 
and metabolites displayed potent biological activity against Staphylococcus aureus, one 
of the six bacterial ESKAPE pathogens. 
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  Equisetin   Ent-equisetin   Altersetin 
   
Altertoxin I   Pyrophen 
Figure 3.4. Chemical structures of equisetin, ent-equisetin, altersetin, altertoxin I, and pyrophen. 
These compounds were used to validate the LC-MS/MS protocols and databases developed. 
 
Liquid Chromatography MS (LC-MS) and Liquid Chromatography Tandem-MS 
(LC-MS/MS) spectral profiles were generated for each crude extract. In order to remove 
hydrophobic metabolites incompatible with LC-MS/MS solvent system, test extracts 
were partitioned between hexanes and 1:3 H2O:MeOH . Comparison of nonpartitioned 
and partitioned extracts indicated a higher yield of hydrophilic metabolites that could be 
evaluated by LC-MS/MS after removal of hydrophobic components. However, both 
partitioned and non-partitioned extracts had the same metabolite profile (Figure 3.5.). 
Extracts were subjected to LC-MS with a standardized elution gradient to generate a 
metabolite chromatographic profile. Crude extracts were then subjected to Automatic 
LC-MS/MS experiments. The Automatic LC-MS/MS experimental protocol utilized the 
same standardized elution gradient as the LC-MS experiment, with CID energies of 
0mV, 10mV, and 40mV selected to match data provided in most public databases. 
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Figure 3.5. Comparative LC-MS Chromatograms of HF14-17C-3B crude extract and partitions. 
The 1:3 H2O:MeOH partition (“MeOH Part.) contained a higher yield of metabolites than the non-
partitioned crude extract (“Crude”). 
 
LC-MS and LC-MS/MS chromatograms were evaluated with AgilentTM Qualitative 
Analysis software. Automated compound identification protocols were used to identify 
distinct metabolites in each LC-MS/MS experiment and to group fragmentation profiles 
for each metabolite; retention time (RT) and HRMS were verified with the LC-MS 
chromatogram for each extract (Figure 3.6.). Two public accurate mass LC-MS/MS 
databases, METLIN-AMRT-PCDL and Mycotoxins-AMRT-PCDL, were utilized to 
identify metabolites. Our protocol was verified with equisetin and ent-equisetin, which 
were both correctly identified in crude extracts with the Mycotoxin-AMRT-PCDL. 
However, other compounds (altersetin, altertoxin I, and pyrophen) were not identified in 
the crude extract by any of the public databases, as Tandem-MS profiles for those 
metabolites have not been previously reported or generated in silico. While public 
databases provide an accurate first tier of dereplication, we sought to develop an in-
house database specific to our fungal extracts to complement the existing public 
databases.   
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Figure 3.6. Mass Spectroscopic profile of equisetin. (A) HRESIMS profile of equisetin extracted 
from (B) the LC-MS chromatogram of crude KML14-75MG-C8, (C) with automatic MS/MS 
fragmentation pattern at 0mV, 10mV and 40mV (C). 
 
3.3.3. Baker Lab Fungal Metabolite Database 
A Tandem-MS Baker Lab Fungal Metabolite Database was constructed using 
Agilent Personal Compound Database and Library (PCDL) software. Of the pure 
compounds isolated from our lab, 45 new and known compounds have been isolated 
from both Floridian and Asian mangrove endophyte fungi. Each compound entry within 
the PCDL contains the HRESIMS, Tandem MS fragmentation profile, and chemical 
structure generated from IUPAC International Chemical Identifier (InChI). The Baker 
Lab Fungal Metabolite Database was verified with the test extracts KML14-75MG-C8 
and HF14-17C-3B. In both extracts, all known compounds were identified in the Baker 
Lab Fungal Metabolite Database. A second round of verification was performed on a 
separate extract (HF14-52C-2A), which was grown independently of the test extracts 
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and also contained equisetin. Equisetin was identified from the Tandem MS profile of 
the crude extract using the Baker Lab Fungal Metabolite Database. 
3.3.4. Mass-Guided Toxin Extraction 
 The second stage of the dereplication protocol is the extraction of known and 
toxic metabolites once they were identified in crude extracts. In order to develop an 
extraction protocol, KML14-75MG-C8 was used as a test crude extract, with equisetin 
and ent-equisetin as toxins being targeted for extraction.  
 Extraction of toxins and known compounds was directed by the LC-MS profile of 
the crude extracts. Following identification of nuisance compounds, the crude extract 
was subjected to preparative Reverse Phase (RP) HPLC using H2O and MeOH. As with 
the LC-MS and MS/MS experiments, a standard elution gradient was utilized to 
maximize separation of components in the crude extract, while also retaining time 
efficiency. Fractions were collected based on 220nm UV absorption (Figure 3.7.). 
 
Figure 3.7. RP HPLC Chromatogram of KML14-75MG-C8 with elution gradient (blue) and 220nm 
UV trace (black). Fraction collection (red) is labeled, with fraction 10 containing equisetin and ent-
equisetin.  
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 The separated fractions were individually subjected to LC-MS analysis, and the 
fraction containing equisetin and ent-equisetin (fraction 10) were identified by 
HRESIMS. The remaining fractions were recombined, and, along with the crude extract 
and the fraction containing the extracted equisetin were screened against S. aureus. As 
indicated in Table 3.1., the crude extract was biologically active against S. aureus 
(MIC= 100μg/mL), as was the fraction containing the extracted toxins (MIC= 50μg/mL). 
However, the remaining extract was inactive against S. aureus, indicating that the 
biological activity against S. aureus can be attributed to the toxins, with no other 
metabolites displaying significant activity.   
Table 3.1. Biological Activity of KML14-75MG-C8 fractions against Staphylococcus aureus before 
and after toxin extraction 
Extract MIC  (μg/mL) 
KML14 Crude 100 
KML14 Crude (Toxin 
Extracted) 
Inactive 
Extracted equisetin 50 
 
 The two stages of our dereplication strategy are aimed at identifying and 
extracting known and toxic compounds from our fungi. As a full illustrative example, 
KML14-75MG-C8 was subjected to LC-MS and LC-MS/MS experiments, and both 
equisetin and ent-equisetin were identified in the crude extract from their Tandem MS 
profiles by both our private and public databases. Following identification of these 
mycotoxins, a mass-directed HPLC extraction of equisetin and ent-equisetin was 
performed, and the remaining extract was rescreened for biological activity against S. 
aureus. With no activity in the toxin-extracted extract, this crude extract can be 
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successfully deprioritized as a source of potential new, bioactive chemistry with 
relatively little chromatographic separation. 
3.4. Proof of Concept:  Isolation of a New Natural Product 
 Following the creation of the Tandem-MS database, several fungal extracts were 
evaluated for their potential bioactive chemistry. One fungal isolate, HF14-37B-1B, was 
isolated from mangrove tissue in the Tampa Bay area. Initial screening of the isolated in 
DNMTi modified growth conditions displayed biological activity against Staphylococcus 
aureus, and the fungus was subsequently grown in large scale and extracted. Though 
the crude extract displayed no biological activity, the extract was subjected to Normal 
Phase (NP) Medium Pressure Liquid Chromatography (MPLC), and several of the 
resulting fractions displayed biological activity. One fraction, H, displayed biological 
activity to 50μg/mL. However the low mass of the fraction resulted in it being rejected for 
further analysis in favor of other fractions.  
 The HRESIMS of HF14-37B-1B-H indicated once major component, with a large 
number of minor contaminants. The Tandem MS profile for the fraction was evaluated in 
both the Baker Lab Fungal Metabolite Database, and METLIN-AMRT-PCDL and 
Mycotoxins-AMRT-PCDL databases: in all searches, there were no matches for the 
major component in the fraction. Following our dereplication and prioritization protocol, 
the extract was selected for further study.  The fraction was subjected to reverse phase 
(RP) High Performance Liquid Chromatography (HPLC) with H2O and ACN, leading to 
the purification of compound 1 (Scheme 3.2.).  
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Compound 1 was determined to have a molecular formula of C10H9NO3 based on 
HRESIMS (m/z 192.0666 [M+H]+). Evaluation of the 1H and 13C NMR spectra indicated 
the presence of a 1,2-disubstituted benzene ring, two carbonyls, and a deshielded 
methyl and methine (Table 3.2). 
 
 Scheme 3.2. Isolation of MAK 12 
 
 2D NMR spectra (gCOSY, gHMBC) were used to determine the structure of 1. 
gCOSY correlations between positions 6-9 verified the 1,2-disubstituted aromatic ring, 
and the spin system comprising positions 3  and 10. The carbon shift of positions 5 (δC 
172.2) and 5a (δC 122.0) and gHMBC correlations between positions 5 and 6 indicated 
that position 5 was a benzylic ester carbonyl. Similarly, the shift of position 9a (δC 138.7) 
indicated a benzylic amine or amide. The chemical shifts of positions 3 (δC 68.8) and 10 
(δC 20.1), and gHMBC correlations between positions 10 and 2 (δC 175.5) supported 
their linking the benzylic ester and benzylic amide, providing the completed structure of 
1 (Figure 3.9.). Position 3 represents the only stereocenter in 1. Stereochemistry was 
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determined by optical rotation and comparison to synthetic derivatives of 1 with known 
absolute stereochemistry.17 The specific rotation of 1 ([𝛼]𝐷
25= -37.0) indicated an S- 
confirmation of position 3. Compound 1 was biologically active against S. aureus at 
50μg/mL (261.72 µM). 
Table 3.2. 1D NMR data for 1in MeOH-d4. 
Pos δCb δH (m, J(Hz))a 
2 175.7 --- 
3 68.8 4.20 (q, 6.8, 1 H) 
5 172.2 --- 
5a 122 --- 
6 128.4 
7.70 (dd, 7.7, 1.4., 
1 H) 
7 123.5 7.14 (m, 1 H) 
8 132.7 7.47 (m, 1 H) 
9 121.5 
8.50 (dd, 8.0, 1.0, 1 
H) 
9a 138.7 --- 
10 20.1 1.40 (d, 6.8, 3 H) 
   
a 1H NMR recorded at 500 MHz, reported in ppm 
(multiplicity, J-coupling (in Hz), integration); b 13C 
shifts are taken from HMBC spectrum and 
multiplicity is taken from HSQC spectrum. 
 
 
 
 
 
 
Figure 3.8. Structure of compound 1. Important 
gCOSY (bold) and gHMBC (arrow) correlations 
are shown.  
 
 
The isolation and identification of 1 is significant for several reasons. 
Interestingly, though it is a new natural product, compound 1 has been reported as an 
intermediate in the synthesis of various 4-quinazolinones in 1963.18 The original 
synthesis was undertaken to produce natural product mimics, as 4-quinazolinones were 
determined to be important structural components to plant alkaloids.18 Importantly, 1 
represents a new compound that was isolated in accordance with our two-stage 
dereplication strategy, in a fraction that would otherwise have been deprioritized due to 
low mass. It serves as a verification that our dereplication strategies can be used to 
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evaluate the metabolite profile of extracts quickly, and aid in identifying and isolating 
new, bioactive natural products 
3.5. Summary and Conclusions 
 The ability to identify known and toxic compounds early has become critical in 
microbial natural products drug discovery. Every year, thousands of new compounds 
are reported in the literature, adding to the already impressive number of bioactive 
secondary metabolites derived from fungi and other microbes. Numerous strategies 
utilize NMR, Tandem MS, and structural databases in order to identify known chemistry 
and prioritize new compound isolation. Many public Tandem MS databases exist with 
experimental and in silico fragmentation patterns for a wide array of fungal metabolites, 
and private databases tailored to specific fungal libraries can be highly effective in 
identifying known and toxic compounds.  
 Our fungal library contains thousands of extracts with a range of biological 
activity. However, chemical investigation efforts have been hindered by repeated 
isolation of toxins and known compounds. We developed a two-stage mass 
spectrometry based dereplication strategy in order to identify these nuisance 
compounds in crude extracts, remove them, and assess the remaining metabolites. 
Standardized Tandem MS experiments were used to build a private database of fungal 
metabolites isolated in our lab, which was used to successfully identify toxins from 
crude extracts without any chromatographic separation. In order to extract these toxins, 
a standardized HPLC experiment, guided by HRESIMS profiles of crude extract, was 
used to successfully extract the toxins, while the rest of the extract could be tested for 
biological activity.  
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Finally, our dereplication strategies were validated as a tool to aid in the 
discovery of new, bioactive compounds. A fungal extract, previously deprioritized due to 
low mass, was evaluated in our two-stage dereplication protocol. The extract had no 
known metabolites identified in our databases, and a new, bioactive benzoxazepine was 
subsequently isolated. The discovery of this compound demonstrates the importance of 
dereplication strategies and the efficiency with which they can be used to discover new 
natural products.  
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CHAPTER FOUR: 
FRIOMARAMIDE: NEW PENTAPEPTIDE ISOLATED FROM ANTARCTIC SPONGES 
 
4.1. The Impact of Marine Natural Products 
4.1.1. The Chemical and Biological Diversity of the World’s Oceans 
The world’s oceans, covering ~70% of the Earth’s surface, represent the largest 
source of biological and chemical diversity on the planet.1 This is especially true of 
animal biodiversity. Of the reported animal phyla, only one is exclusively terrestrial, 
while 15 phyla occur exclusively in marine environments.2 Of the marine-dwelling 
animals, invertebrates are the most taxonomically diverse, including phyla like Porifera, 
Cnidaria, Annelida, Arthropoda, Mollusca, and Echinodermata (Figure 4.1.), and 
together represent 60% of marine animals.3,4 Many of these invertebrates are sessile 
and soft-bodied, and so must rely on potent chemical defenses to deter predators,1 
making them promising sources of unique, bioactive chemistry. 
 
Figure 4.1. Marine invertebrates. From left: Staghorn Coral (Acropora cervicornis) of the phylum 
Cnideria (Photo by Albert Kok, Dutch Wikipedia), red encrusting sponge (Monanchora arbuscular) 
of the phylum Porifera (Photo by Nick Hobgood), and Crown of Thorns starfish (Acanthaster 
planci) of the phylum Echinodermata (Photo by Jon Hanson). 
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Over the last half-century, marine sources have become a promising source of 
new, bioactive chemistry. Some of the earliest research in marine natural products 
began in the 1950s, alongside advancements in taxonomic and sampling studies for 
marine organisms.5 In the following three decades, the field of marine natural products 
became more productive and economic, until, in the late 1980s and 1990s, marine 
natural products became a prevalent and prolific source of new natural products.6 From 
1990-2005, approximately 8000 new marine natural products were reported in the 
literature, with almost 70% reported from marine invertebrates.4  
 
Figure 4.2. Trend in the occurrence of natural product scaffolds. Most novel natural product 
scaffolds occur very few times throughout marine natural product chemistry.7  
 
The chemistry of marine invertebrates has been shown to be both more novel 
and have more significant and relevant biological activity than terrestrial natural 
products.8 In a comparative analysis of marine and terrestrial natural product scaffolds 
reported in Dictionary of Natural Products (version 17:2) and Dictionary of Marine 
Natural Products (2007.6), more than 70% of marine natural product scaffolds were 
exclusively utilized by marine organisms, while terrestrial natural product scaffolds had 
significantly less exclusivity. Of the ~4000 marine natural product scaffolds, only a few 
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are prevalent throughout marine natural products, with more than half of the scaffolds 
occurring in only one incidence within reported marine natural products (Figure 4.2.).7 
In a National Cancer Institute preclinical cytotoxicity screen, more than 1% of marine 
derived samples displayed anti-tumor potential, compared to less than 0.5% of 
terrestrial samples screened (Figure 4.3.).9  
 
Figure 4.3. Distribution of samples with significant cytotoxicity in a per-clinical screening by the 
NCI. Raw number of active samples shown in italics.9 
 
 Terrestrial natural products represent the bulk of natural product-related 
marketed drugs.8 However, marine-sourced drugs are quickly becoming relevant in the 
clinical pipeline. Five marine-source drugs are currently reported on the market: 
cytarabine (Ara-C, Cytosar-U®) and vidarabine (Ara-A, Vira-A®), synthetic sponge 
natural product mimics approved as anti-cancer and anti-viral drugs, respectively, 
ziconotide (Prialt®), a synthetic equivalent to a cone snail derived peptide, approved to 
treat severe chronic pain, trabectedin (Yondelis®), an anti-cancer drug first isolated 
from a marine tunicate, and eribulin mesylate (HalavinTM), a sponge natural product 
derivative most recently approved to treat breast cancer (Figure 4.4.).8 In addition to 
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marketed drugs, there are many marine-related lead compounds in various stages of 
the clinical pipeline, addressing disease areas like cancer, pain managements, 
Alzheimer’s disease, wound healing, and anti-inflammation.1 As more novel chemistry is 
reported, marine natural products will continue to play a critical role in the development 
of new marketed drugs for a variety of disease targets. 
 
              
    Cytarabine, Ara-C     Vidrabine, Ara-A   Trabectedin 
                
             Eribulin Mesylate     Ziconotide 
Figure 4.4. Chemical structures of marine natural product-related compounds that have been 
approved as marketed drugs. 
 
4.1.2. Cold Water Oceans: Hotbeds of Chemical Discovery 
Despite the large body of research in the marine environment, most marine 
natural products have been isolated from tropical or temperate waters. For obvious 
reasons of sampling, climate, and accessibility, cold water organisms are significantly 
less studied than their warm water counterparts.10 Of new marine natural products 
reported from 1990-2010, over 60% were reported from organisms collected at or north 
of the equator, with tropical organisms accounting for 51% of new marine natural 
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products.4 As marine natural products interest has intensified, research in the polar 
regions has expanded rapidly, leading to new interest in cold water ecosystems for 
chemical diversity.4 
 
Figure 4.5. The Antarctic Circumpolar Current (ACC). (a) The geographical area and direction of 
the ACC, and (b) the surface speed from a high resolution numerical model. Copyright Anthony 
Thompson, Caltech, http://web.gps.caltech.edu/~andrewt/research/acc.html, 2018. 
 
The cold water Southern Oceans surrounding Antarctica are some of the largest 
in the world, comprising 10% of total world ocean area.11 Antarctica’s geographic and 
biological isolation is largely attributed to the Antarctic Circumpolar Current (ACC). 
Though relatively slow, it is the largest ocean current in the world and circulates 
clockwise around the continent,11 transporting nutrient rich deep water throughout the 
waters surrounding Antarctica while isolating it from northern oceans (Figure 4.5.).12 
Antarctica has a highly productive marine ecosystem.13 The benthic waters are 
dominated by large macroalgal forests and rich assemblages of sponges, soft corals, 
bryozoans, hydroids, and ascidians.12 Many of these soft-bodied invertebrates 
experience intense predation, so the chemical diversity of Antarctic marine invertebrates 
is high.10 
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  Antarctic invertebrates have provided numerous unique and bioactive natural 
products (Figure 4.6.). The meridianins and palmerolide A, both isolated from Antarctic 
tunicates, exhibit biological activity in cancer-related assays.10 Many of the meridianins 
prevent cell proliferation and encourage cell apoptosis,14 while palmerolide A has 
extremely potent and selective melanoma cell line activity.15 The shagenes, isolated 
from an unidentified Antarctic octocoral, are tricyclic sesquiterpenes. Shagene A 
exhibits notable activity against the infected macrophage stage of the Leishmania 
donovani parasite, with no cytotoxicity to the mammalian host cell.16 The red alga, 
Plocamium cartilagineum, has been extensively studied ecologically, and has been 
found to produce new polyhalogenated monoterpenes like anverene.10 Anverene 
displays an inhibitory effect on vancomycin-resistant Enterococci faecium (VRE).17 The 
vast biological and chemical diversity in the Southern Oceans surrounding Antarctica 
make it a promising source of new natural products. 
                      
                 Meridianin A                      Palmerolide A 
 
 
 
       Shagene A           Anverene 
 
 Figure 4.6. New, biologically active natural products isolated from Antarctic invertebrates. 
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4.1.3. Porifera as Sources of Unique Natural Products 
Sponges of the phylum Porifera are among the most well-known and well-studied 
marine invertebrates. Sponges are morphologically and taxonomically diverse, are 
widespread in the world’s oceans, and play important ecological roles in benthic 
waters.18 Chemically, sponges predominate natural products drug discovery. Of all 
marine invertebrate natural products reported from 1990-2010, nearly half were 
reported from phylum Porifera, with approximately 250 new natural products reported 
on average every year.4 In the last ten years, more new sponge natural products (~2500 
total) have been reported than any other marine invertebrate phyla (Figure 4.7.).19 
Sponges, being soft-bodied and sessile organisms, produce a variety of chemical 
defense to deter predators, prevent fouling, and to cultivate their extensive symbiotic 
microorganisms.20,21 
 
 Figure 4.7. Number of new compounds reported per phyla from 2001-2010.19  
The natural products isolated from sponges are known for their chemical novelty 
and potent, broad biological activity.19 New natural products from sponges have been 
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reported to be active in many different disease areas, including anti-fungal, 
immunosuppressive, cancer cell lines, and as antibiotics.19,22  Both cytarabine and 
vidrabine, FDA approved drugs, are derived from metabolites of Caribbean sponge 
Tethys crypta.8,23 In addition to marketed drugs, there are sponge metabolites 
throughout the clinical pipeline: Zalypsis®, a phase II anti-tumor agent, is derived from 
renieramycin isolated from Netropsia sp.,23 IPL512602, a phase II anti-inflammatory 
asthma control agent, is a synthetic derivative of a steroid isolated from Petrosia 
contignata,1 and PM050489 and PM060184, phase I chlorinated polyketides with 
antimitotic activity, were isolated from Lithoplocamia lithistoides.23  
While most reported sponge chemistry is from tropical or temperate climates, 
sponges from polar regions, and Antarctica specifically, have produced unique new 
chemistry (Figure 4.8.). The discorhabdin alkaloids are a widespread and important 
class of compounds found in Lactrunculiidae family of sponges found in the southern 
oceans.10 In addition to acting as feeding deterrents for the producing sponges,24 many 
discorhabdins, like discorhabdin R, display activity against select Gram-positive 
(Staphylococcus aureus, Micrococcus luteus) and Gram-negative (Serratia 
marcenscens, Escherichia coli) bacteria.10 Membranolides C and D, natural product 
artefacts isolated from Antarctic sponge Dendrilla membranosa, are active against 
Gram-negative bacteria and fungi, as well as tropical parasite Leishmania donavani.10 
Caminatal, an aldehyde sesterterpene, was isolated from Suberites caminatus. Though 
lacking biological activity, caminatal, and its related compounds, represent novel 
molecular scaffolds reported from Antarctic sponges.10,25 
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 Discorhabdin R   Membranolide C   Caminital 
Figure 4.8. Chemical structures of Antarctic sponge metabolites discorhabdin R, membranolide 
C, and caminatal. 
 
4.2. Research Objectives 
The ocean contains the largest source of animal biodiversity on the planet. Of the 
many animal phyla that inhabit the oceans, marine invertebrates, often soft-bodied and 
sessile, produce an abundance of biologically active natural products to serve as a 
chemical defense. Marine natural products have been, and continue to be, an 
invaluable source of unique, novel, and bioactivity chemistry. Despite the vast size and 
biological diversity of the world’s cold oceans, marine natural products are 
predominated by research in tropical and temperate climates. The cold water oceans 
surrounding Antarctica represent a largely untapped chemodiversity source.  
In an effort to explore the full potential of marine Antarctic invertebrates, the 
Baker lab has made efforts to study a variety of Antarctic invertebrates, in particular 
sponges, for new chemistry. Herein is presented the study of a collection of unidentified 
Antarctic sponges for new, bioactive natural products.  
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4.3. Isolation and Characterization of Friomaramide 
4.3.1. Collection, Extraction, and Compound Isolation 
A collection of sponges, collectively documented as NBP13-24, were collected by 
trawling in the Scotia Arc on the Nathanial B. Palmer research vessel. The sponges had 
many morphological similarities, though a taxonomic identification was not possible 
(Figure 4.9.). The sponges were initially handled and extracted individually: each 
sponge was extracted for two 24 hr periods in 1:1 DCM:MeOH, followed by a 24hr 
extraction in 1:1 H2O:MeOH. The individual extracts were subjected to analysis with 
Liquid Chromatography Mass Spectrometry (LC-MS) in order to compare the chemical 
extracts. Of the eight collected sponges, seven of them had identical metabolite profiles; 
the similar extracts were combined together for analysis.  
 
 Figure 4.9. Voucher photos of the eight sponges identified as NBP13-24. Photo by Bill J. Baker. 
 
The crude extract was subjected to Normal Phase (NP) Medium Pressure Liquid 
Chromatography (MPLC) with a hexane and EtOAc gradient with a 1:3 MeOH:EtOAc 
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wash. Of the fractions collected, none displayed biological activity. However, fraction E 
was prioritized for analysis based on the fraction’s mass and 1H NMR spectrum. 
Fraction E was subjected to iterative rounds of separation with reversed phase (RP) 
HPLC using H2O and MeOH. Following purification with RP HPLC with H2O and ACN, 
compound 1 was isolated (Scheme 4.1). 
 
 Scheme 4.1. Isolation of compound 1. 
4.3.2. Structure Elucidation of Friomaramide 
Compound 1 was determined to have a molecular formula of C46H67N7O6 based 
on HRESIMS (m/z 814. 5243 [M+H]+, calculated 814.5231). Evaluation of the 1H and 
13C NMR spectra (Table 4.1.) indicated that compound 1 contained several nitrogen-
bearing methyl groups, multiple aromatic rings, and multiple carbonyls. 2D NMR 
techniques (gCOSY, gHMBC) were utilized to determine the structure of the molecule 
(Figure 4.10.). gHMBC data correlated each methine proton (δH 5.00-5.50) to two 
carbonyls (δC 173.0-173.5) and a single amide methyl (δH 2.75-3.10). These 
correlations suggested that the molecule was a linear peptide, with each α-position 
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methine displaying long-range correlations to the carbonyl of its own amino acid, and of 
the subsequent amino acid in the chain. Interestingly, all of the amino acids displayed 
nitrogen methylation, indicated by the number of and gHMBC correlations of the amide 
methyl groups. With this knowledge, gCOSY correlations were used to construct each 
amino acid within the molecule. An alanine, phenylalanine, valine, and two isoleucine 
residues were thus identified.  
 
 
Friomaramide 
 
Figure 4.10. Chemical structure of 1. Important gCOSY (bold) and gHMBC (arrows) correlations 
are shown. 
 
 The sequence of these five methylated amino acids was established using 
gHMBC correlations, supported by analysis of the ESIMS fragmentation pattern. In 
particular, the α-position methine protons, which displayed correlations to the adjacent 
amide carbonyls, were critical to establishing the peptide sequence. The α-position 
methine of Phe (δH 5.14) displayed a gHMBC correlation to its own amide carbonyl (δC 
172.4), but no other amino acid carbonyls, indicating it was a terminal amino acid. The 
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α-position methine of Val (δH 5.34) displayed correlations to both its own carbonyl (δC 
170.3) and Phe carbonyl; the α-position methine of Ala displayed correlations to its own 
carbonyl (δC 173.3) and the Val carbonyl; the α-position methine of Ile-1 (δH 5.09) 
displayed correlations to its own carbonyl (δC 170.4) and the Ala carbonyl; the α-position 
methine of Ile-2 (δH 5.34) displayed correlations to its own carbonyl (δC 170.8) and the 
Ile-1 carbonyl, with Ile-2 terminating the amino acid sequence. The sequence of Phe-
Ala-Val-Ile-Ile was thus established. The N-terminus of the peptide was determined to 
be acetylated, indicated by gHMBC correlations between the acetyl methyl group (δH 
1.92) and the α-position methine of Phe (δH 5.14), and the acetyl carbonyl (δC 171.5). 
The C-terminus was composed of a decarboxylated tryptophan residue, tryptenamine. 
gCOSY and gHMBC correlations were used to establish the structure of the tryptamine. 
Though no long-range correlations existed between this residue and the rest of the 
peptide, the ESIMS fragmentation verified its placement in the peptide, completing the 
structure of 1. 
 The sequence of the amino acids was verified independently from the 
ESIMS fragmentation pattern (Figure 4.11.) utilizing Protein ProspectorTM software. 
When provided with major ESIMS mass fragments, the software verified the sequence 
of amino acids of 1 to be Ac-Me Phe-Me Ala-Me Val-Me Ile-Me Ile, with the remainder 
of the structure attributed to the tryptophan residue. This allowed verification of the 
structure of 1. 
Stereochemical analysis of 1 performed with Marfey’s analysis as described in 
the literature.26,27 Briefly, 1 was hydrolyzed to the individual amino acids, which were 
then derivatized with the chiral Marfey’s reagent, FDAA (Nα-(2,4-dinitro-5-flourophenyl-
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L-alaninamide), which allowed the amino acid enantiomers to be distinguishable from 
one another chromatographically. These reaction products were evaluated using a 
routine LC-MS experiment, and, by comparison to similarly derivatized amino acid 
standards, the configuration of each amino acid in 1 could be determined. The absolute 
configuration of 1 was determined to be D-Phe-L-Val-L-Ala-L-Ile-L-Ile (Figure 4.11.).  
 
 Figure 4.11. ESIMS fragmentation pattern of 1. 
4.3.3. Biological and Chemical Importance 
Friomaramide (1) is a pentapeptide with full nitrogen methylation of the amino 
acids. Peptides are typically biosynthesized by non-ribosomal peptide synthases 
(NRPS), which can insert a multitude of post-translational modification into the 
synthesized peptides. Nitrogen methylation is one such modification to individual amino 
acids as they are added to the growing peptide.28 Peptide methylation is attractive in 
drug discovery, as non-methylated peptides have poor pharmacokinetic properties 
(short in vivo half-life, poor oral availability) that can be improved by methylation.29 
Though uncommon, naturally occurring single or multiple N-methylated peptides have 
been reported from marine and terrestrial sources.26,30–34 
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Table 4.1. 1D NMR data for friomaramide (1) in MeOH-d4 . 
Pos δCb δH (m, J(Hz))a 
Ac   
CO 171.3 --- 
 -Me 24.1 1.92 (s, 3 H) 
Phe   
CO 172.4 --- 
α 53.0 5.14 (t, 15.7, 1 H) 
β 40.2 2.90 (m, 1 H) 
  3.05 (m, 1 H) 
1 136.9 --- 
 2/6 129.5 7.28 (br m, 2 H) 
 3/5 129.0 7.25 (br m, 2 H) 
4 130.0 7.23 (br m, 1 H)  
N-Me 32.1 2.86 (s, 3 H) 
Val   
CO 170.3 --- 
α 60.4 5.34 (d, 10.9, 1 H) 
β 29.9 2.21 (m, 1 H) 
γ 20.8 0.80 (d, 7.3, 3 H) 
γ' 18.7 0.83 (d, 7.3, 3 H) 
N-Me 32.7 2.78 (s, 3 H) 
Ala   
CO 173.3 --- 
α 53.3 5.17 (m, 1 H) 
β 16.8 1.20 (d, 7.0, 3 H) 
N-Me 32.1 2.95 (s, 3 H) 
Ile-1   
CO 170.4 --- 
α 59.3 5.09 (d, 11.0, 1 H) 
β 24.1 1.98 (m, 1 H) 
β-Me 19.0 0.76 (d, 6.5, 3 H) 
γ 31.8 1.29 (m, 2 H) 
δ 17.1 0.60 (d, 6.5, 3 H) 
N-Me 32.7 3.01 (s, 3 H) 
 
 
a 1H NMR recorded at 800 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C 
NMR recorded at 200 MHz. 
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Table 4.1. (Continued) 1D NMR data for friomaramide (1) in MeOH-d4 . 
Pos δCb δH (m, J(Hz))a 
Ile-2   
CO 170.8 --- 
α 60.4 5.14 (m, 1 H) 
β 35.8 2.10 9m, 1 H) 
β-Me 20.0 0.81 (d, 6.5, 3 H) 
γ 29.4 1.32 (m, 2 H) 
δ 19.3 0.76 (d, 6.5, 3 H) 
N-Me 35.0 3.09 (s, 3 H) 
Tryptenamine   
2 128.1 7.22 (s, 1 H) 
3 109.8 --- 
3a 126.7 --- 
4 118.1 7.60 (d, 7.8, 1 H) 
5 122.0 7.08 (t, 7.2, 1 H) 
6 125.4 7.15 (t, 7.2, 1 H) 
7 111.1 7.36 (d, 7.8, 1 H) 
7a 136.8 --- 
α 121.6 6.59 (d, 8.2, 1 H) 
β 125.9 6.31 (d, 8.3, 1 H) 
 
a 1H NMR recorded at 500 MHz, reported in ppm (multiplicity, J-coupling (in Hz), integration); b 13C 
NMR recorded at 200 MHz.         
 
Interestingly, both terrestrial32 and warm water marine derived33,34 Aspergillus spp. have 
been reported to produced highly methylated peptides with an acetylated N-terminus, 
and a tryptenamine C-terminus, similar to friomaramide. It is not uncommon for primary 
production of natural products to be carried out by host-associated fungi.10,31 Given the 
structural similarities of friomaramide to marine fungal peptides, primary production may 
be carried out by fungi associated with the collected sponges, rather than the sponges 
themselves. 
Of reported N-methylated peptides, the vast majority are only highly methylated.  
Full nitrogen methylation of the amino acids is exceptionally rare, with only a single 
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class of compounds, isolated from tropical brown cyanobacteria Lyngbya majuscula, 
reported in the literature.26 Friomaramide is, to the best of our knowledge, the only other 
fully methylated natural product peptide, the first isolated from a cold water organism, 
and the first isolated from a non-cyanobacterial organism.  
4.4. Summary and Conclusions 
 The cold water oceans surrounding Antarctica contain vast biological and 
chemical diversity. Despite this, the study of marine invertebrate chemistry has lagged 
behind research efforts in tropical and temperate water oceans. Given the unique and 
bioactive natural products reported from such cold water invertebrates, our lab seeks to 
tap the vast potential for new lead compounds. 
 A collection of unidentified sponges were collected in the Scotia Arc of the 
Southern Ocean. After extraction, chemically similar sponges were combined and 
subjected to chemical investigation. From the collection of sponges, a new compound, 
friomaramide (compound 1) was isolated, and its structure elucidated using NMR and 
MS techniques. Friomaramide is a pentapeptide, and is the first naturally occurring 
peptide displaying full nitrogen methylation. 
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APPENDIX A: 
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER TWO 
Microbial Isolation Protocol 
Screening Protocol 
Microbial Scale Up Protocol 
Chromatographic Isolation Protocol 
Compound Data 
 
Microbial Isolation Protocol 
 Solid media was made from a variety of nutrient components (sabouraud 
dextrose broth (SDB), potato dextrose broth (PDB), trypticase soy broth/agar (TSA), 
Actinomycete Isolation Agar, Malt Extract Agar) and agar produced by DBTM DifcoTM, 
and, along with FisherbrandTM petri dishes, were purchased through Fisher Scientific. 
Glycerol, chloramphenicol, cycloheximide, and nystatin were purchased from Sigma 
Aldrich®. 
 Media components were mixed according to manufacturer’s instructions, heated, 
autoclaved, and set in petri dishes.  
 Mangrove tissue was collected from the bark, stem, roots, and leaves of the tree. 
Tissue was surfaced sterilized in IPA, cut into 1 cm3 pieces, and embedded in four 
locations on each agar plate per media type. Field plates were incubated at 20-25 oC 
(room temperature) for 1-4 weeks, or until all fungal isolates had been harvested or the 
plate had become overgrown with fungal growth. Small, 1 cm3 pieces of fungal isolates 
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harvested from the field plate were transferred to a new plate of the same media plate, 
and incubated at 28 oC. Transfer and isolation procedure was repeated until a single 
fungal culture was isolated onto a plate, at which point the isolate was transfer to an 
untreated SDB agar plate. Upon growth on the SDB plate, 10-12 1cm3 pieces were 
stored in a cryotube in 20% glycerol for long term storage. Descriptions of each fungal 
isolate were recorded. 
Screening Protocol 
 Epigenetic modulators sodium butyrate (HDACi) and 5-azacytidine (DNMTi) were 
purchased from Sigma Aldrich®. Modifiers were introduced as a 100 µM solution of 
each modifier in SDB, stored in 1.25 mL EppendorfTM microcentrifuge tubes purchased 
from Fisher Scientific. Rice media was made by autoclaving 1 g of unbleached and 
untreated brown rice, purchase from HoneyVille FarmsTM, in 3 mL of DI water in a 20 
mL scintillation vial. CorningTM 96-well 200 µL clear polypropylene microplates and 
FisherbrandTM 96-well DeepWellTM polypropylene microplates were purchased from 
Fisher Scientific. 
 Each fungal isolate was grown on an SDB agar plate. Once a colony was 
established, three 1 cm3 pieces were transferred into 1.25 mL each of untreated SDB, 
HDACi treated SDB, and DNMTi treated SDB in a sterilized microcentrifuge tube. Each 
mixture was agitated and poured over a vial of rice media. Once inoculated with fungal 
culture, each vial was incubated for 21 days at 28 oC. Following incubation, fungal 
colonies were inspected for growth and contamination. Fungal samples that had not 
grown to a sufficient size (covering approximately half the rice media) were incubated 
for another 7 days and reevaluated; fungal colonies that displayed bacterial or multiple 
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fungal growths were discarded. Fungal colonies that were to be extracted were first 
doused with MeOH to dampen the surface of the fungal mat, after which 10 mL of 
EtOAc was added to each vial, and the rice and fungal colony were broken apart with a 
metal spatula and suspended in the EtOAc to extract overnight. After approximately 24 
hrs of extraction, the supernatant of each vial was transferred into a clean, pre weighed 
vial, while the solid rice and fungal colony were discarded. The collected extract was 
dried down and weighed, and redissolved to 5 mg/mL in DMSO. From each extract, five 
duplicate plates were made with 150 µL/well in CorningTM polypropylene microplates to 
be sent for bioassay. Of the remaining extract, duplicate FisherbrandTM DeepWellTM 
polypropylene plates were made each with 2 mL/well for long term storage of extracts.  
Microbial Scale Up Protocol 
 Scaled up growth protocols for fungal cultures were developed to mirror the small 
scale HTS growth protocol, and were followed for all scaled up fungi. In a Type 3T 
Unicorn bag, 300 g of rice and 500 mL of dionized water were mixed, and the bag heat 
sealed and autoclaved. Fungi selected for scale up were regrown on a SDB agar plate. 
Several 1 cm3 pieces of the fungal colony were transferred into triplicate FisherbrandTM 
50 mL Falcon Tubes, each containing 50 mL each of untreated SDB, 100 µL HDACi 
SDB solution, or 100 µL DNMTi SDB solution. Each set of falcon tubes were agitated 
and poured over the rice, and the rice physically agitated to mix the rice, SDB solution, 
and fungal cubes. Bags were taped closed, and incubated at 28 oC for 21 days. After 
the incubation period, a cotton swab was used to piece the fungal colony, and was 
swabbed on an SDB agar plate to check for bacterial contamination or multiple fungal 
growths in the bag. The top of the fungal mat was dowsed in MeOH, and the rice and 
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fungi broken apart and transferred into a large beaker. In order to replicate the 
proportions of MeOH and EtOAc present in the small scale screening, the fungal colony 
was extracted first for 24 hrs in 750 mL of 1:3 MeOH:EtOAc. Following this first 
extraction period, the supernatant was filtered, and the fungi was subjected to two more 
24 hr extraction periods in EtOAc. After filtering the supernatant from each of these 
extractions, the rice and fungal colony were discarded, and the extract was dried down 
and weighed, with a small portion set aside and redissolved in DMSO for bioassay.  
Chromatographic Isolation Protocol 
 Medium Pressure Liquid Chromatography (MPLC) was performed using a 
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia 
column (Figure A1., Figure A3.). Normal Phase High Performance Liquid 
Chromatography (HPLC) was completed with a gradient of hexanes to EtOAc over 
40min on a semi-preparative Phenominex® silica column (10 μm, 100 Å, 250 x 10 mm) 
using ELSD and UV detection. Reverse Phase HPLC was completed with a gradient of 
H2O to either MeOH or ACN on an analytical Phenominex® C18 column (5 μm, 100 Å, 
250 x 4.6 mm) using ELSD and UV detection (Figure A2., Figure A3., Figure A4.). 
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Figure A1. NP MPLC Chromatogram of KLM14-75MG-C8-DNMTi. Elution gradient (percent 
EtOAc, blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace 
(green), and fraction of interest are shown. 
 
 
Figure A2. NP HPLC Chromatogram of KML14-75MC-C8-DNMT-E. Elution gradient (blue), 
ELSD trace (black) and UV absorbance at 320 nm (yellow) are shown. Equisetin and ent-
equisetin were isolated from the major components.  
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Figure A3. NP MPLC Chromatogram of HF14-17C-3B-DNMTi. Elution gradient (percent EtOAc, 
blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green), 
and fractions of interest are shown. 
 
 
Figure A4. NP HPLC Chromatogram of HF14-17C-3B-DNMT-G5. Elution gradient (blue), ELSD 
trace (black) and UV absorbance at 320 nm (yellow) are shown. Altersetin was isolated from the 
major component. 
 
 
Figure A5. NP HPLC chromatogram of HF14-17C-3B-DNMT-G7. Elution gradient (blue), ELSD 
trace (black) and UV absorbance at 320 nm (yellow) are shown. Altertoxin I was isolated from the 
major component. 
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Figure A6. RP HPLC chromatogram of HF14-17C-3B-DNMT-G. Elution gradient (blue), ELSD 
trace (black) and UV absorbance at 320 nm (yellow) are shown. Pyrophen was isolated from 
major component, fraction 2. 
 
 
Compound Data 
Equisetin (1): C22H31NO4; HRESIMS m/z 356.2227 [M+H-H2O]+ (C22H30NO3, calculated 
356.2225), m/z 374.2375 [M+H]+ (C22H32NO4 calculated, 374.2331), m/z 397.2251 
[M+Na]+ (C22H31NO4Na calculated, 3597.2227); 1H NMR (500 MHz, CDCl3) δ ppm 0.90 
(m, 1 H), 0.92 (d, 6.5, 3 H), 1.09 (q, 12.0, 1 H), 1.09 (q, 9.5, 1 H), 1.47 (br s, 3 H), 1.52 
(d, 5.0, 3 H), 1.52 (m, 1 H), 1.69 (br s, 1 H), 1.75 (br m, 1 H), 1.79 (m, 1 H), 1.83 (m, 1 
H), 1.97 (br m, 1 H), 3.06 (s, 3 H), 3.32 (br s, 1 H), 3.67 (br t, 5.0, 1 H), 3.9 (dd, 11.4, 
6.0, 1 H), 4.07 (br d, 11.0, 1 H), 5.17 (m, 1 H), 5.25 (m, 1 H), 5.40 (br s, 1 H), 5.40 (br s, 
1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.3 (CH3, C-12), 17.8 (CH3, C-15), 22.5 (CH3, 
C-16), 27.2 (CH3, C-7’), 28.4 (CH2, C-10), 33.5 (CH, C-8), 35.7 (CH2, C-9), 38.6 (CH, C-
6), 40.0 (CH, C-11), 42.2 (CH2, C-7), 45.0 (CH, C-3), 48.8 (C-2), 60.3 (CH2, C-6’), 66.1 
(CH, C-5’), 100.0 (C, C-3’), 126.6 (CH, C-4 or C-5), 127.0 (CH, C-14), 129.9 (CH, C-4 or 
C-5), 130.8 (CH, C-13), 177.0, (C-2’), 190.9 (C-1), 200.2 (C-4’).  
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 Figure A7. 1H NMR spectrum (500 MHz, CDCl3) of equisetin (1). 
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 Figure A8. 13C NMR spectrum (125 MHz, CDCl3) of equisetin (1). 
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 Figure A9. 1H-13C gHSQC NMR spectrum (500 MHz, CDCl3) of equisetin (1). 
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 Figure A10. 1H-1H gCOSY NMR spectrum (500 MHz, CDCl3) of equisetin (1). 
105 
 
MAK 8_gHMBC_01.fidesp
F2 Chemical Shif t (ppm)
50
100
150
200
 
 Figure A11. 1H-13C gHMBC NMR spectrum (500 MHz, CDCl3) of equisetin (1). 
 
Ent-equisetin (2): C22H31NO4; HRESIMS m/z 356.2230 [M+H-H2O]+ (C22H30NO3, 
calculated 356.2225), m/z 374.2370 [M+H]+ (C22H32NO4 calculated, 374.2331), m/z 
397.2253 [M+Na]+ (C22H31NO4Na calculated, 3597.2227); 1H NMR (500 MHz, CDCl3) δ 
ppm 0.90 (q, 12.0, 3 H), 0.92 (d, 6.5, 3 H), 1.09 (q, 12.0, 1 H), 1.04 (m, 1 H), 1.48 (br s, 
1 H), 1.56 (d, 5.0, 3 H), 1.48 (m, 1 H), 1.66 (br s, 1 H), 1.77 (br m, 1 H), 1.80 (m, 1 H), 
1.83 (m, 1 H), 1.96 (br m, 1 H), 3.05 (s, 3 H), 3.36 (br s, 1 H), 3.66 (br t, 3.5, 1 H), 3.85 
(dd, 12.0, 3.5, 1 H), 4.05 (br d, 6.5, 1 H), 5.16 (dd, 15.0, 6.0, 1 H), 5.24 (dq, 15.0, 5.0, 1 
H), 5.41 (br s, 1 H), 5.42 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.0 (CH3, C-
12), 18.2 (CH3, C-15), 22.6 (CH3, C-16), 27.0 (CH3, C-7’), 28.0 (CH2, C-10), 33.3 (CH, 
C-8), 35.6 (CH2, C-9), 38.5 (CH, C-6), 42.0 (CH, C-11), 44.6 (CH2, C-7), 45.0 (CH, C-3), 
48.0 (C-2), 60.0 (CH2, C-6’), 66.6 (CH, C-5’), 100.0 (C, C-3’), 126.2 (CH, C-4 or C-5), 
127.1 (CH, C-14), 129.8 (CH, C-4 or C-5), 130.4 (CH, C-13), 176.8 (C-2’), 190.7 (C-1), 
198.8 (C-4’). 
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 Figure A12. 1H NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2). 
 
 
 
 Figure A13. 13C NMR spectrum (125 MHz, CDCl3) of ent-equisetin (2). 
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 Figure A14. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2). 
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 Figure A15. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2). 
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Figure A16. 1H- 13C gHMBC NMR spectrum (500 MHz, CDCl3) of ent-equisetin (2). 
 
Altersetin (3):  C24H33NO4; HRESIMS m/z 382.2374 [M+H-H2O]+ (C24H32NO3, calculated 
382.2382), m/z 400.2491 [M+H]+ (C24H34NO4, calculated 400.2488), m/z 422.2304 
[M+Na]+ (C24H33NO4Na, calculated 422.2307); 1H NMR (500 MHz, CDCl3) δ ppm 0.82 
(m, 1 H), 0.86 (d, 7.0, 3 H), 0.99 (m, 1 H), 1.03 (m, 1 H), 1.20 (d, 6.0, 3 H), 1.35 (s, 3 H), 
1.51 (m, 1 H), 1.55 (m, 1 H), 1.64 (d, 6.7, 3 H), 1.72 (m, 1 H), 1.80 (m, 1 H), 1.82 (m, 1 
H), 1.89 (m, 1 H), 3.43 (m, 1 H), 3.60 (br s, 1 H), 3.90 (m, 1 H), 5.24 (dd, 14.0, 4.0, 1 H), 
5.36 (m, 1 H), 5.45 (m, 1 H), 5.50 (dq, 15.2, 5.5, 1 H), 5.71 (dd, 10.9, 3.0, 1 H), 5.88 (dd, 
11.0, 3.0, 1 H), 9.22 (br s, 1 H); 13C NMR (125 MHz, CDCl3) δ ppm 14.0 (CH, C-22), 
18.9 (CH3, C-21), 21.2 (CH, C-24), 22.7 (CH3, C-23), 28.0 (CH2, C-9), 33.0 (CH, C-11), 
36.0 (CH2, C-10) 38.0 (CH C-13), 39.1 (CH, C-8), 42.0 (CH2, C-12), 45.5 (C-7), 45.5 
(CH, C-16), 66.1 (CH3, C-16), 66.9 (CH, C-5), 100.0 (C-3), 126.2 (CH, C-15), 128.5 
(CH, C-20), 130.0 (CH, C-17), 131.0 (CH, C-14), 131.5 (CH, C-18), 131.5 (CH, C-19), 
182.8 (C-2), 191.5 (C-4), 199.1 (C-6). 
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Figure A17. 1H NMR spectrum (500 MHz, CDCl3) of altersetin (3). 
 
 
 Figure A18. 13C NMR spectrum (125 MHz, CDCl3) of altersetin (3). 
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 Figure A19. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of altersetin (3). 
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 Figure A20. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of altersetin (3). 
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 Figure A21. 1H- 13C gHMBC NMR spectrum (500 MHz, CDCl3) of altersetin (3). 
 
Altertoxin I (4): C20H16O6; HRESIMS m/z 317.0811 [M+H-2H2O]+ (C20H13O4, calculated 
317.0814), m/z 335.0915 [M+H-H2O]+ (C20H15O5, calculated 335.0915), m/z 353.1021 
[M+H]+ (C20H17O6, calculated 353.1025);  1H NMR (600 MHz, MeOH-d4) δ ppm 2.43 (td, 
14.3, 4.1, 1 H), 2.69 (dt, 16.7, 3.1, 1 H), 2.91 (dd, 16.1, 12.0, 1 H), 3.01 (m, 1 H), 3.07 
(d, 5.5, 1 H), 3.08 (m, 1 H), 3.17 (m, 1 H), 4.76 (m, 1 H), 7.02 (d, 8.8, 1 H), 7.07 (d, 8.8, 
1 H), 7.81 (d, 8.7, 1 H), 7.83 (d, 8.7, 1 H), 12.34  (s, 1 H), 12.69 (s, 1 H); 13C NMR 
(taken from gHMBC spectrum) δ ppm 33.9 (CH2, C-5), 34.4 (CH2, C-6), 47.7 (CH2, C-8) 
51.9 (CH, C-6b), 66.1 (CH, C-7), 69.2 (C-6a), 116.1 (C-9a), 116.9 (C-3a), 117.6 (CH, C-
11), 120.0 (CH, C-2), 122.7 (C-12b), 124.4 (C-12a), 132.4 (CH, C-12), 132.6 (CH, C-1), 
135.4 (C-12c), 139.1 (C-9b), 162.0 (C-10), 162.3 (C-3), 202.0 (C-9), 204.9 (C-4). 
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 Figure A22. 1H NMR spectrum (600 MHz, MeOH-d4) of altertoxin I (4). 
 
 
 Figure A23. 1H- 13C HSQC NMR spectrum (600 MHz, MeOH-d4) of altertoxin I (4). 
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 Figure A25. 1H- 1H gCOSY NMR spectrum (600 MHz, MeOH-d4) of altertoxin I (4). 
 
 
 Figure A26. 1H- 13C HMBC NMR spectrum (600 MHz, MeOH-d4) of altertoxin I (4). 
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Pyrophen (5): C16H17NO4; HRESIMS m/z 288.1230 [M+H]+ (C16H18NO4, calculated 
288.1236), 310.1045 [M+Na]+ (C16H17NO4Na , calculated 310.1056); 1H NMR (500 
MHz, CDCl3) δ ppm 1.96 (s, 3 H), 3.09 (d, 7.5, 2H), 3.75 (s, 3 H), 5.0 (q, 7.7, 1 H), 5.41 
(d, 2.1, 1 H), 5.74 (d, 2.0, 1 H), 5.96 (d, 8.5 1H), 7.12 (m, 2 H), 7.12 (m, 2 H), 7.25 (m, 3 
H), 7.25 (m, 3 H), 7.25 (m, 3 H); 13C NMR (taken from gHMBC spectrum) δ ppm 20.9 
(CH3, C-2), 38.0 (CH2, C-β), 52.7 (CH, C-α), 55.5 (CH3, C-4’-OMe), 87.7 (CH, C-5’), 
100.3 (CH, C-3’), 126.6 (CH, C-4’’), 128.7 (1H, C-3’’), 128.7 (CH, C-5’’), 129.0 (CH, C-
6’’), 136.6 (C-1’’), 162.5 (C-2’), 162.9 (C-6’), 171.3 (C-1), 172.0 (C-4’). 
 
 
Figure A27. 1H NMR spectrum (500 MHz, CDCl3) of pyrophen (5). 
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 Figure A29. 1H- 13C gHSQC NMR spectrum (500 MHz, CDCl3) of pyrophen (5). 
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 Figure A30. 1H- 1H gCOSY NMR spectrum (500 MHz, CDCl3) of pyrophen (5). 
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 Figure A31. 1H- 13C gHMBC NMR spectrum (500 MHz, CDCl3) of pyrophen (5). 
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Table A1. Biological Activity of 1-5 against Staphylococcus aureus. 
Compound 
IC50 
(µM) 
Equisetin (1) 2.67 
Ent-equisetin (2) 26.7 
Altersetin (3) 125.24 
Altertoxin I (4) Inactive 
Pyrophen (5) 696.1 
 
 
. 
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APPENDIX B: 
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER THREE 
LC-MS/MS Experimental Parameters 
Database Construction Protocol 
Chromatographic Isolation Protocol 
Compound Data 
 
LC-MSMS Experimental Parameters 
 LC-MS/MS Experiments were performed on an AgilentTM LC-QToF using 
Electrospray Ionization (ESI). Crude extracts were dissolved and partitioned between 
hexanes and 1:3 H2O:MeOH. Crude extracts and pure compounds were made to 1 
mg/mL and 0.1 mg/mL, respectively, in MeOH. Standard Reverse Phase liquid 
chromatography was completed with an elution gradient of H2O to ACN on a 
Phemonenex® Kinetex® C-18 column (2.6 μm, 100 Å, 150x 3 mm). The instrument 
experimental parameters are as indicated (Table B.1.). 
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Table B.1. Acquisition Parameters for LC-MS/MS Experiments.  
HiP Sampler    Pump   
Injection Volume 10.0 μL  Flow 0.40 mL/min 
Injection with needle 
wash Yes  Solvent A 
H2O+0.1% Formic 
acid 
Needle Wash Mode Flush Port  Solvent B 
ACN+0.1% Formic 
acid 
Needle Wash Time 3.0 sec  Pressure Limit Min 0.00bar 
Draw Speed 100.0 μL/min  
Pressure Limit 
Max 600.00 bar 
Eject Speed 100.0 μL/min  Stop Time 14.00 min 
Draw Position 0.0 min  Posttime 1.00 min 
Equilibration Time 0.0 sec    
Sample Flush-out Factor 
5.0x Inj. 
Volume 
 
   
 
Time Table        
Time [min] A [%] B [%] Flow [mL/min]  
0.00 90.00 10.00 0.40  
0.01 98.00 2.00 0.40  
2.00 98.00 2.00 0.40  
10.00 2.00 98.00 0.40  
12.00 2.00 98.00 0.40  
12.01 98.00 2.00 0.40  
14.00 98.00 2.00 0.40  
     
QToF         
General         
Ion Source Dual AJS ESI  Plot and Centroid Data Storage Threshold 
Ion Polarity Positive  MS Abs Threshold 200 
Data Storage Both  Rel. Threshold (%) 0.01 
LC Stream MS  
MS/MS Abs 
Threshold 5 
Stop Time As Pump  Rel. Threshold (%) 0.01 
Cycle Time 1.7 s       
Source         
Gas Temp 300 oC  
MS TOF 
Fragmentor 140 V 
Drying Gas 8 l/min  MS TOF Skimmer 65 V 
Nebulizer 30 psig  
MS TOF OCT 1 RF 
Vpp 750 V 
Sheath Gas Temp 300 oC  
TOF Collision 
Energy 0 V 
Sheath Gas Flow 11 l/min     
Dual AJS ESI Vcap 4000 V     
Caillary 0.00 uA     
Nozzle Voltage 500 V     
Chamber 0.00 UA       
Acquisition         
Spectral Parameters         
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Table B.1. (Continued) Acquisition Parameters for LC-MS/MS Experiments. 
Acquisition         
Spectral Parameters         
MS   MS/MS Auto 
Mass Range Min 40 m/z  Mass Range Min 40 m/z 
Mass Range Max 1300 m/z  Mass Range Max 1300 m/z 
Acquisition Rate 1 spectra/s  Acquisition Rate 5 spectra/s 
Acquisition Time 
1000 
ms/spectrum  Acquisition Time 200 ms/spectrum 
Transients/spectrum 5971  Transients/spectrum 1118 
     Isolation Width Medium (~4 m/z) 
      Collision Energy 
0 mV, 10 mV 40 
mV 
 
QToF     
Precursor Selection    Chromatogram   
Max Precursor Per 
Cycle 3  Label TIC 
Abs. Threshold 1000 counts  Expt Type MS 
Rel. Threshold (%) 0.01%  Polarity Effect Both 
Active Exclusion Disabled  Offset 15 
Excluded after 3 Spectra  Y-Range 10000000 
Released after 0.5 min    
Reference Mass       
Mass Correction Enable 
Ref. 
Masses   
Detection Windown 100 ppm 121.0508   
Min Height 1000 counts 922.0098   
 
Database Construction Protocol 
 LC-MS/MS data was processed using AgilentTM MassHunter Qualitative Analysis 
B.05.00. Database was generated using AgilentTM Personal Compound and Database 
Library (PCDL) software. Compounds were identified and spectra were collected and 
extracted from MassHunter Qualitative Analysis and converted to compound entry files 
in the PCDL according to manufacturer’s instructions. For each compound entry in the 
PCDL, the compound name, high-resolution mass, and MS/MS profile was added. For 
each compound, a lnchl structural code was generated using ACD/Labs 2016 
ChemSketch software and was entered into the PCDL. All compounds within an extract 
were analyzed with public databases, METLINTM-AMRT-PCDL and Mycotoxins-AMRT-
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PCDL, and our own private database, Baker Lab Fungal Metabolite PCDL, using 
MassHunter Qualitative Analysis as specified by manufacturer’s instructions. 
Chromatographic Isolation Protocol 
Medium Pressure Liquid Chromatography (MPLC) was performed using a 
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia 
column (Figure B1.). Normal Phase High Performance Liquid Chromatography (HPLC) 
was completed with a gradient of hexanes to EtOAc over 40 min on a semi-preparative 
Phenominex® silica column (10 μm, 100 Å, 250 x 10 mm) using ELSD and UV 
detection. Reverse Phase HPLC was completed with a gradient of H2O to MeOH on a 
semi-preparative Phenominex® C18 column (10 μm, 100 Å, 250x 10 mm) (Figure 3.7.), 
or with a gradient of H2O to either ACN or MeOH on an analytical Phenominex® C18 
column (5 μm, 100 Å, 250 x 4.6 mm) using ELSD and UV detection (Figure B2.). 
 
 
Figure B1. NP MPLC chromatogram of HF14-37B-1B-DNMTi. Elution gradient (percent EtOAc, 
blue), UV absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green), 
and fractions of interest are shown. 
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Figure B2. RP HPLC chromatogram of HF14-37B-1B-DNMTi. Elution gradient (blue), ELSD trace 
(black) and UV absorbance at 320 nm (yellow) are shown.3-methyl-4,1-benzoxazepine-2,5(1H, 
3H)-dione was isolated from major component. 
 
Compound Data 
3-methyl-4,1-benzoxazepine-2,5(1H, 3H)-dione (1): C10H9NO3; HRESIMS m/z 174.0568        
[M+H-H2O]+ (C10H8NO2, calculated 174.0555), m/z 192.0666 [M+H]+ (C10H10NO3, 
calculated 192.0660); UV (MeOH) λmax (log ε) 230 (1.78); [𝛼]𝐷
25= -37.0 (c 0.1, MeOH); IR 
(thin film) 3250, 3000, 2940, 1730, 1700, 1590, 1550, 1250 cm-1; 1H NMR (400 MHz, 
MeOH-d4) δ ppm 1.40 (d, 6.8, 3 H), 4.20 (q, 6.8, 1 H), 7.14 (m, 1 H), 7.47 (m, 1 H), 7.70 
(dd, 7.7, 1.4, 1 H), 8.50 (dd, 8.0, 1.0, 1 H); 13C NMR (taken from gHMBC spectrum) δ 
ppm 20.1 (CH3, C-10), 68.8 (CH, C-3), 121.5 (CH, C-9), 122.0 (C-5a), 123.5 (CH, C-7), 
128.4 (CH, C-6), 132.7 (CH, C-8), 138.7 (C-9a), 172.2 (C-5), 175.7 (C-2). 
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 Figure B3. 1H NMR spectrum (400 MHz, MeOH-d4) of compound 1. 
 
 
 Figure B4. 1H-13C gHSQC NMR spectrum (500 MHz, MeOH-d4) of compound 1. 
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 Figure B5. 1H-1H gCOSY NMR spectrum (500 MHz, MeOH-d4) of compound 1. 
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 Figure B6. 1H-13C gHMBC NMR spectrum (500 MHz, MeOH-d4) of compound 1. 
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APPENDIX C: 
EXPERIMENTAL AND SUPPORTING DATA FOR CHAPTER FOUR 
Chromatographic Isolation Protocol 
Compound Data 
 
Chromatographic Isolation Protocol 
 Medium Pressure Liquid Chromatography (MPLC) was performed using a 
Combiflash Rf 200i MPLC, using ELSD and UV detection with a RediSepRf 80 g silicia 
column (Figure C1.). Reverse Phase HPLC was completed with a gradient of H2O to 
MeOH on a semi-preparative Phenominex® C18 column (10 μm, 100 Å, 250 x 10 mm) 
(Figure C2) or with a gradient of H2O to either ACN or MeOH on an analytical 
Phenominex® C18 column (5 μm, 100 Å, 250 x 4.6 mm) using ELSD and UV detection 
(Figure C3.). 
 
125 
 
 
Figure C1. NP MPLC chromatogram of NBP13-24-6. Elution gradient (percent EtOAc, blue), UV 
absorbance at 254 nm (pink), 280 nm (red) and 320 nm (yellow), ELSD trace (green), and 
fractions of interest are shown. 
 
 
Figure C2. RP HPLC chromatogram of NBP13-24-6. Elution gradient (blue), ELSD trace (black) 
and UV absorbance at 320 nm (yellow) are shown. Friomaramide (1) was isolated from labeled 
fraction. 
 
 
Figure C3. . RP HPLC chromatogram of NBP13-24-6. Elution gradient (blue), ELSD trace (black) 
and UV absorbance at 320 nm (yellow) are shown. Friomaramide (1) was isolated from major 
component 
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Compound Data 
Friomaramide (1): C46H67N7O6; HRESIMS m/z 814.5243 [M+H]+ (C46H68N7O6, 
calculated 814.5231), m/z 836.5051 [M+Na]+ (C46H67N7O6Na, calculated 836.5050); UV 
(MeOH) λmax (log ε) 230 (2.81);  [𝛼]𝐷
25=  -150 (c 0.1, MeOH); IR (thin film) 3450, 3050, 
2980, 2960, 1700, 1680, 1635, 1500, 1240 cm-1; 1H NMR (800 MHz, MeOD) δ ppm 0.60 
(d, 6.5, 3 H), 0.76 (d, 6.5, 3 H), 0.76 (d, 6.5, 3 H), 0.80 (d, 7.3, 3 H), 0.81 (d, 6.5, 3 H), 
0.83 (d, 7.3, 3 H), 1.20 (d, 7.0, 3 H), 1.29 (m, 2 H), 1.32 (m, 2 H), 1.92 (s, 3 H), 1.98 (m, 
1 H), 2.10 (m, 1 H), 2.21 (m, 1 H), 2.78 (s, 3 H), 2.86 (s, 3 H), 2.90 (m, 1 H), 2.95 (s, 3 
H), 3.01 (s, 1 H), 3.05 (m, 1 H), 3.09 (s, 3 H), 5.09 (d, 11.0, 1 H), 5.14 (m, 1 H), 5.14 (t, 
15.7, 1 H), 5.17 (m, 1 H), 5.34 (d, 10.9, 1 H), 6.31 (d, 8.3, 1 H), 6.59 (d, 8.2, 1 H), 7.08 
(t, 7.2, 1 H), 7.15 (t, 7.2, 3 H), 7.22 (s, 1 H), 7.23 (br m, 1 H), 7.25 (br m, 2 H), 7.28 (br 
m, 2 H), 7.36 (d, 7.8, 1 H), 7.60 (d, 7.8, 1 H); 13C NMR (200 MHz, MeOH-d4) δ ppm 16.8 
(CH3, Ala-β), 17.1 (CH3, Ile-1-δ), 18.7 (CH3, Val-γ'), 19.0 (CH3, Ile-1-β-Me), 19.3 (CH3, 
Ile-2-δ), 20.0 (CH3, Ile-2-β-Me), 20.8 (CH3, Val-γ), 24.1 (CH3, Ac –Me), 24.1 (CH2, Ile-1-
β), 29.4 (CH, Ile-2-γ), 29.9 (CH, Val-β), 31.8 (CH2, Ile-1-γ), 32.1 (CH3, Phe-N-Me), 32.1 
(CH3, Ala-N-Me), 32.7 (CH3, Val-N-Me), 32.7 (CH3, Ile-1-N-Me), 35.0 (CH3, Ile-2-N-Me), 
35.8 (CH2, Ile-2-β), 40.2 (CH2, Phe-β), 53.0 (CH, Phe-α), 53.3 (CH, Ala-α), 59.3 (CH, 
Ile-1-α), 60.4 (CH, Val-α), 60.4 (CH, Ile-2-α), 109.8 (Trypt-3), 111.1 (CH, Trypt-7), 118.1 
(CH, Trypt-4), 121.6 (CH, Trypt-α), 122.0 (CH,  Trypt-5), 125.4 (CH, Trypt-6), 125.9 
(CH, Trypt-β), 126.7 (Trypt-3a), 128.1 (CH, Trypt-2), 129.0 (CH, Phe- 3/5), 129.5 (CH, 
Phe- 2/6), 130.0 (CH, Phe-4), 136.8 (Trypt-7a), 136.9 (Phe-1), 170.3 (Val-CO), 170.4 
(Ile-1-CO), 170.8 (Ile-2-CO), 171.3 (Ac-CO), 172.4 (Phe-CO), 173.3 (Ala-CO).  
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Figure C4. 1H NMR spectrum (800 MHz, MeOD) for friomaramide (1). 
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 Figure C5. 13C NMR spectrum (200 MHz, MeOH-d6) for friomaramide (1). 
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Figure C6. 1H-13C gHSQC NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1). 
 
 
Figure C7. 1H-1H gCOSY NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1). 
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Figure C8. 1H-13C gHMBC NMR spectrum (800 MHz, MeOH-d6) for friomaramide (1). 
 
Marfey’s Analysis 
 A portion of 1 (0.3 mg) was hydrolyzed at 120 oC with 6M HCL for 24 hrs. A 0.1 
M NaHCO3 solution (200 μL) was added to the dried hydrolysate of 1, as well as to L- 
and D- amino acids standards of N-Me valine, N-Me alanine, N-Me phenylalanine, N-Me 
isoleucine, N-Me allo-isoleucine. A solution of Marfey’s reagent, FDAA (Nα-(2,4-dinitro-
5-flourophenyl-L-alaninamide) in acetone (25 mg in 50 μL) was added to each 
hydrolysate and standard, and each was incubated at 90 oC for 10 minutes. To quench 
each reaction, 100 μL of 2 M HCL was added and then diluted with 300 μL of 
acetonitrile. The Marfey’s derivatives of the hydrolysate and standards were analyzed 
using LC-MS-ToF with a Phemonenex® Kinetex® C-18 column (2.6 μm, 100 Å, 150 x 3 
MAK 13_HMBC.fidesp
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100
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130 
 
mm), with an elution gradient of 75% H2O/25% acetonitrile acidified with 0.1% formic 
acid to 20% H2O/80% acetonitrile acidified with 0.1% formic acid over 10 minutes at a 
0.4 mL/min flow rate. Comparison of retention time and mass of each Marfey’s 
derivative of the hydrolysate and standard was used to determine the absolute 
stereochemistry of 1 (Table C1.). 
Table C1. Marfey’s analysis of friomaramide (1). 
N-Me 
Amino Acid 
Retention Time 
(min) 
Friomaramide Amino 
Acid Retention Time 
(min) 
D-Ala 5.77  
L-Ala 5.91 5.89 
D-Ile 6.94  
L-Ile 7.57 7.56 
D-allo-Ile 7.20  
L-allo-Ile 7.39  
D-Phe 7.31 7.32 
L-Phe 7.19  
D-Val 7.41  
L-Val 6.98 7.03 
 
